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Abstract     
Sickle Cell Pain Management During the First 24 Hours of Inpatient Care Compared to 
the National Heart Lung and Blood Institute Clinical Practice Guidelines for the 
Emergency Department: A Quality Improvement Project  
Genice T. Nelson, DNP 
 
University of Connecticut, 2017 
 
This quality improvement project addressed the clinical practice patterns for the first 24 
hours of the hospitalized adult for inpatient care in comparison to the established 
guidelines for the emergency department treatment of sickle cell pain with the NHLBI 
2002 and 2013 guidelines in a suburban teaching hospital. The analysis focused on the 
treatment provided which included information regarding patient assessments, 
utilizations for intravenous fluids, oxygen administration, the choice of pain medications 
including opioids, NSAIDS, and other adjuvants.  A post hoc retrospective chart review 
was conducted with data abstraction on the current clinical practice utilized during the 
inpatient admission which identified deficits that will lead to the creation of a clinical 
dashboard for ongoing quality improvement and outcome monitoring. This process was 
guided by the principles of the Dartmouth Clinical Microsystem’s and the 5 P’s: 
Purpose, Patients, Professionals, Processes, and Patterns for a complete system 
change. The overall focus for change was intravenous fluids and rates, opioid titration 
for pain relief, and patient reported desired pain goals.                                                                                               
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Chapter 1 
Background of the Problem 
Sickle cell disease is a lifelong, genetic, hematologic disorder in which the body 
produces abnormally shaped erythrocytes (Telfair, 2003). Normal red blood cells or 
erythrocytes are traditionally bi-concave discs that move easily through the blood 
vessels and carry oxygen to all parts of the body (Ballas, 2005). However, “sickle cells” 
are hard, sticky, and tend to clump together. The cells then get stuck and literally block 
the flow of blood to the organs and limbs, causing pain, anemia, and organ damage 
(Ballas, 2010). A genetic mutation in -globin gives rise to altered hemoglobin, the 
oxygen-carrying molecule, found within erythrocytes. This variation has been identified 
as a genetic “switch” of valine for a glutamate. This results in abnormally formed 
hemoglobin, which distorts the shape of red blood cells in individuals with sickle cell 
disease. 
In the African American community, the incidence of sickle cell disease is 
approximately 1:400 live births. The incidence of the sickle cell trait, the carrier status, 
occurs in 1:12 live births, while Hemoglobin C trait occurs in 1:50, β+ thalassemia trait 
occurs in 1:100, βº Thalassemia trait occurs in 1:1000, and Sickle Hemoglobin C 
Disease occurs in 1:1250 (Whitten, 2001). In the United States, sickle cell disease 
affects more than 100,000 people, while globally sickle cell disease affects more than 
2.5 million individuals (Ballas, 2010; Hassel, 2010; Mvundura, 2009). Sickle cell disease 
is common in parts of Africa, particularly Sub-Saharan Africa. Sickle cell disease is also 
common in Spanish-speaking countries in South America, Central America, and parts of 
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the Caribbean. In addition, sickle cell disease is prevalent in Saudi Arabia, India, and 
Mediterranean countries such as Turkey, Greece, and Italy (Smith et al., 2005; Whitten, 
2001).  
Because of the nature of sickle cell disease as a chronic illness, the burden of 
care can be tremendous on families and communities. The most common reason that 
persons with sickle cell disease engage medical care and acute care services is that 
they frequently suffer from vaso-occlusive crisis pain episodes (Adams-Graves, P., 
Ostric, E. J., Martin, M., Richardson, P., & Lewis, J.B., 2008). In fact, patients with sickle 
cell disease utilize more emergency department services than patients with other more 
common chronic illnesses such as diabetes, asthma, and hypertension (Ballas, 2009; 
Ballas & Lusardi, 2005; Brousseau, Owens, Mosso, Panepinto, & Steiner, 2010; Moore, 
Charache, Terrin, Barton, & Ballas, 2000). Many researchers suggest this may be 
directly related to the lack of consistent care and management of adult sickle cell 
disease patients in both the inpatient and the outpatient settings (Aisiku et al., 2007; 
Ballas & Lusardi, 2005; Epstein, 2005).  
Pain management for an adult in vaso-occlusive crisis includes the timely 
administration of adequate doses of analgesia, intravenous fluids, and adjuvant anti-
inflammatory treatments that assist the patient to maintain a tolerable level of pain and 
to function without impairment (Frei-Jones, Baxter, Rogers, & Buchanan, 2008; Frei-
Jones, Field, & DeBaun, 2009; Lopez, Flenders, Davis-Moon, Corbin, & Ballas, 2007). 
Guidelines specific to the management of sickle cell pain episodes have been 
developed to reduce provider bias based on race and gender of the patients and for 
facilitation of equal access to quality care during a pain episode in most care settings 
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including the home, primary care/out-patient, and emergency department. However, 
these guidelines do not extend to the in-patient setting (Benjamin et al., 1999; NHLBI, 
2004; Platt et al., 2002; Rees, 2003). 
Purpose of Practice Change 
A quality improvement project to identify and enhance key clinical practices in a 
vaso occlusive crisis of an adult with sickle cell disease was conducted. The pain 
episode treatments during the initial 24 hour period of hospitalization were compared to 
the NHLBI emergency department guidelines. The literature currently does not include 
data that compares inpatient management of adults with acute SCD pain during the 
first, critical 24 hours with the NHLBI emergency department management guidelines.  
This project compared inpatient clinical practice patterns in a single setting to the 
most current (2002) NHLBI emergency department guidelines. Clinical practice pattern 
deficits were identified in order to test and refine dashboard measures: patient 
assessments, utilization of intravenous fluids, oxygen administration, and choice of pain 
medications including opioids, NSAIDS, and other adjuvants to be tracked over time.  
The clinical dashboard is a provider tool to monitor patient care. The clinical dashboard 
was the measure to monitor high quality care and guide clinical practice patterns based 
on these identified clinical practice deficits. The dashboard enabled the clinical practice 
changes required to correct these deficits to remain easily identified and correctable 
with systematic monitoring over time.  The measures identified were used to 
recommend microsystems change using the Dartmouth model. 
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The following questions were addressed for each unique individual hospital 
admission during the preceding one year: 
1. What are the differences between clinical management approaches within the 
first 24 hours of inpatient admission at the facility and the national NHLBI 
standards’? 
2. What are the quality improvement outcomes that need to be tracked over time to 
evaluate the closure of identified practice gaps? 
Significance of Project 
The mental and physical challenges of acute and chronic pain coupled with other   
psychosocial issues can become overwhelming and difficult to navigate for patients and 
families (Aisiku et al., 2007; Bediako, Lavender, & Yasin, 2007; Jenerette & Murdaugh, 
2008). Likewise, the uniqueness, complexity, and variability of sickle cell pain in adults 
with SCD make its management very challenging for providers. Pain management for 
an adult in vaso-occlusive crisis includes the timely administration of adequate doses of 
analgesia, intravenous fluids, and adjuvant treatments that assist the patient to maintain 
a tolerable level of pain and to function without impairment (Frei-Jones, Baxter, Rogers, 
& Buchanan, 2008; Frei-Jones, Field, & DeBaun, 2009; Lopez, Flenders, Davis-Moon, 
Corbin, & Ballas, 2007). One of the identified barriers to quality pain management for 
adults listed in the American Pain Foundation Revised Pain Care Bill of Rights as cited 
by the Journal of Pain and Palliative Care Pharmacotherapy (Anonymous, 2004) is that care 
providers often mistrust the patients and characterize patients’ behavior as “drug-
seeking.” Similar barriers have been documented in adults with SCD (Ballas, 2010).  
According to Ballas and Lusardi (2005), judgmental providers – nurses and medical 
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staff – were more likely to provide suboptimal pain management. Yet, for individuals 
with sickle cell disease, the management of acute pain episodes that require hospital 
treatment is an important aspect of their care. It is the responsibility of providers to 
remove the labels of “drug-seeking” and “drug-abusers” and provide non-judgmental 
care for sickle cell disease patients (Ballas & Lusardi, 2005, Maxwell, 1999). 
Guidelines specific to the management of sickle cell pain episodes have been 
developed to facilitate equal access to quality care during a pain episode in all care 
settings including the home, primary care/out-patient, emergency department, with the 
exception of in-patient (Benjamin et al., 1999; NHLBI, 2002; Platt et al., 2002; Rees, 
2003 ).  Limited guidelines are widely available for the management of sickle cell 
disease acute care. Rees (2003) emphasizes the utilization of identification cards with 
baseline information of individualized care for the cardholder, expressing the need for 
urgency and expediency in care management for adults and children. The National 
Institute for Health and Clinical Excellence, 2012 (NICE) has a similar individualized 
patient care focus with the difference being based on patient reporting, which should 
include: frequent assessments, consideration of sickle cell complications while 
managing pain, and following the local protocols for management for the individual 
across the lifespan. The existing NHLBI (2002) guideline for pain management in the 
emergency department for hospitalized adults with sickle cell disease has specific 
recommendations for treatment shown in Table 1. 
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Table 1. NHLBI SCD Vaso-Occlusive Management Recommendations 
Assessment and Reassessments: for the individual’s pain episode 
Initial rapid assessment- 
of acute painful episode 
including pain intensity, 
prompt treatment and 
relief.  
Reassessments – 
frequent reassessments 
every 15-30 minutes after 
the administration of pain 
medications for pain 
intensity, relief, mood, and 
sedation level.  
Response to therapy – 
reported reduction in pain 
intensity of at least 50-
60% from the upper end 
of pain score. 
 
Intravenous hydration: 
Initial fluid should be 5% 
dextrose + half-normal 
saline.  
Add 20 mEq KCI/L 
adjusted for serum 
chemistries.  
Total fluids not to exceed 
1.5 times maintenance 
dose. 
Administration of Oxygen: 2 liters via nasal cannula for patients with pulse oximetry 
of 92-95% 
Administration of Opioids and Adjuvants: Short-acting opioid agonists 
For adults with ≤ 50 kg body weight: 
Morphine: 0.1-0.15 mg/kg every 2-4 
hours (parenteral); 0.30 mg/kg every 3-4 
hours (oral). 
Hydromorphone: 0.015-0.020 mg/kg 
every 3-4 hours (parenteral); 0.06-0.08 
mg/kg every 3-4 hours (oral).  
*Meperidine: not recommended 
For adults with ≥ 50 kg body weight: 
Morphine: 5-10 mg every 2-4 hours 
(parenteral);  
10-30 mg every 3-4 hours (oral). 
Hydromorphone: 1.5 mg every 3-4 hours 
(parenteral); 7.5 mg every 3-4 hours 
(oral).  
Oxymorphone: 1.0-1.5 mg every 6hours 
(parenteral) or 0.5 mg IV and cautiously 
titrate upward. *Meperidine: not 
recommended 
Other routes of administration: Subcutaneous (for the individual with poor or no 
venous access to prevent delays in treatment) and patient controlled analgesia 
(PCA). 
Non-steroidal anti-inflammatory drugs (NSAIDS): 
Ketorolac (parenteral) for inadequate analgesia after optimal titration or when the side 
effects of opioids are problematic (maximum use of 5 days/month).  
Note. NHLBI Guidelines 2002 
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There have been a limited number of studies which demonstrated that 
implementing clinical practice guidelines for the inpatient adult with sickle cell disease 
could provide consistent quality care with positive patient outcomes (Adams-Graves, 
Lamar, Johnson, & Corley, 2008; Ballas & Lusardi, 2005; Givens et al., 2007). Adams-
Graves (2008) created a disease-specific, inpatient hospital care unit within the confines 
of an academic teaching hospital, with the primary purpose of caring for adult sickle cell 
patients.  This disease-specific unit was intended to improve care management of 
adults experiencing vaso-occlusive pain episodes or other complications of sickle cell 
disease. Ballas and Lusardi (2005) developed disease specific treatment guidelines to 
provide optimal management patients with SCD in the hospital setting. Increased 
utilization of the existing guidelines or their adaptation would be one approach to assure 
equal access to the evidence-based treatment guidelines and improve care for this 
patient population given the pain episodes that are endured. Repeated pain episodes’ 
prompt adults with SCD to be hospitalized multiple times. An adult inpatient hospitalized 
with vaso-occlusive crisis episode pain stays for an average of 6.5 days (Adams-
Graves, 2008; Epstein et al 2006). Utilization of these clinical practice guidelines could 
potentially reduce the number of hospital days, decrease the cost of care, increase 
patient satisfaction, improve quality of life, and improve overall pain management 
(Adams-Graves et al., 2008; Frei-Jones et al., 2009).  
Theoretical Framework 
Kolcaba (2001) stated comfort has many aspects and domains. The nurse’s goal 
is to create and maintain a holistic environment and atmosphere in which patients can 
recover and maintain optimal health. Comfort for many is more than just the absence of 
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pain. It is the maintenance of a nurturing, caring, and stable environment that allows the 
patient to have access to the medications and treatments that will alleviate pain and 
other complications in a manner that allows them to flourish in their comfort which was 
used as the theoretical framework for this quality improvement project.   
     The Dartmouth Clinical Microsystem (2005), a systematic approach for quality 
improvement, was used as the methodology to guide the project. The Dartmouth 
Clinical Microsystem (2005) aided in the assessment of the current clinical practice 
patterns in comparison to the NHLBI guidelines: via post-hoc medical record review, 
determining themes from the data abstraction, global aim, and/or specific aims for 
improvement as determined by the data analysis, and the need to change ideas with 
education for the staff, patient, and/or other stakeholders to implement quality 
improvement initiatives. The use of the Dartmouth Clinical Microsystem helped to 
assess the current state of the clinical practice patterns by utilizing the following 
characteristics known as the “5P’s”:    
1. Purpose- set goals for the program to specifically improve the quality of 
care and reduce pain as expeditiously as possible for the hospitalized 
adult experiencing a vaso-occlusive pain event.  
2. Patients- utilize patient characteristics and demographics to determine 
how best to involve the patients in the quality improvement (QI) process.  
3. Professionals- determine team member roles, work hours, satisfaction, 
and then optimize roles for improving the quality of care for patients 
hospitalized with vaso-occlusive pain.  
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4. Processes-Identify the daily nursing processes for the care of these 
patients during the initial 24 hours of hospitalization? What are the usual 
processes?  
5. Patterns- Evaluate potential daily interruptions? What are the similar 
concerns or questions of the patients? When does the team meet? What 
are possible outcomes? These are key components that will be 
addressed with the creation of the dashboard for monitoring this QI 
project.  
Summary of Chapter 
     Sickle cell disease a genetic hematologic red blood cell disorder causes severe pain 
and organ damage that leads to frequent episodic pain requiring medical intervention 
(Ballas & Lusardi, 2010 & Odesina et al., 2010). Considered a rare disease in the 
United States, globally approximately 2.5 million more people are affected with the 
disorder (Ballas, 2010; Hassel, 2010; Mvundura, 2009). This chronic disorder has the 
highest utilization of services, as measured against other chronic disorders such as 
diabetes and hypertension (Ballas, 2009; Ballas & Lusardi, 2005; Brousseau, Owens, 
Mosso, Panepinto, & Steiner, 2010; Moore, Charache, Terrin, Barton, & Ballas, 2000).  
     One of the most important aspects and ultimate goals of pain management is to 
adequately relieve pain, or alleviate pain to a tolerable level (Adams-Graves et al., 
2008; Ballas & Lusardi, 2010; Brousseau et al.,  2010; Frei-Jones et al., 2008; NHLBI, 
2002; Odesina et al., 2010; Smith et al., 2005 ). Determining clinical practice pattern 
deficits to test and refine dashboard measures (patient assessments, utilization of 
intravenous fluids, oxygen administration, and choice of pain medications including 
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opioids, NSAIDS, and other adjuvants) to be tracked over time provided the foundation 
for refining clinical practice patterns and the overall improvement of pain and comfort for 
patients.      
     This quality improvement project was focused on evaluating the clinical practices to 
improve inpatient pain management using the Dartmouth Clinical Microsystem. Many 
researchers have suggested treatment guidelines would aid in the management of the 
hospitalized adult. A methodical literature review was conducted to guide the clinical 
practice pattern data abstraction for pertinent information to guide quality improvement 
recommendations and the clinical dashboard for monitoring ongoing clinical practice 
improvements.   
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Chapter 2 
Literature Review 
Introduction 
This quality improvement project helped to identify current clinical practice 
patterns and determined what and where practice changes were needed to foster 
evidence-based practice for improved management of sickle cell pain in the inpatient 
setting during the initial 24 hours of hospitalization. This review included a 
comprehensive search of Medline, Cinahl, AHRQ Guidelines, DynaMed, Google 
Scholar, and the Cochrane Library. 
The keywords used to search the databases included sickle cell, pain 
management, protocols, pain crisis, sickle cell disease clinical practice guidelines, 
evidence-based clinical practice guidelines for the treatment/management of sickle cell 
pain, sickle cell disease pain management, care of the adult with sickle cell disease, 
pain management for adults with sickle cell disease, sickle cell disease protocols, pain 
crisis guidelines for sickle cell disease, sickle cell treatments, quality improvement for 
sickle cell disease management, and sickle cell practice patterns. Of the 85 listings that 
were retrieved from published studies during the time span of 1985-2015, 21 studies 
met the inclusion criteria. Criteria for a study to be included as part of this systematic 
review were: the study needed to focus on persons with confirmed diagnoses of sickle 
cell disease; and/or the management or treatment of persons in vaso-occlusive crisis; 
and/or the study had to discuss the utilization of information regarding hospital or 
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emergency department use, self-care and management of sickle cell disease, and 
access to treatment for management of sickle cell vaso-occlusive episodes.  
Of the published literature, only one of the studies, a randomized controlled trial, 
met the inclusion criteria as the gold standard for research. The number of peer 
reviewed, randomized controlled, or quantitative studies available in the literature is 
limited to one for adults. This limitation suggests the need for continuing research that 
may improve the quality of care for individuals seeking treatment for vaso-occlusive pain 
episodes. 
A methodical review of the literature was conducted to determine the scope of 
literature available regarding clinical practice patterns for the hospitalized adult with 
sickle cell disease experiencing a vaso-occlusive crisis pain episode. No research 
currently exits that compares inpatient management of adults with acute SCD pain 
during the first, critical 24 hours with the NHLBI emergency department management 
guidelines. 
Research was limited regarding clinical practice guidelines for the care of the 
adult hospitalized and experiencing a vaso-occlusive crisis pain episode. The following 
review includes several aspects of care: psychosocial issues of SCD, mortality/morbidity 
of SCD, provider knowledge, clinical practice patterns, utilization of services, financial 
burden of care, average length of stay (ALOS), and clinical practice guidelines and 
protocols. This information was utilized for determining the current clinical practice 
patterns for the hospitalized adult experiencing a sickle cell vaso-occlusive crisis pain 
episode. 
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Pathophysiology of Vaso-Occlusive Crisis Pain Episodes  
The latest evidence available suggests that sickle cell vaso-occlusive crisis pain 
episodes are the culmination of physiological processes that occur concurrently within 
the body and cause the individual to suffer varying degrees of pain (Ballas, 2010; 
Newcombe, 2002). With the occurrence of low oxygen, the red blood cells undergo 
polymerization, which causes the cells to become rigid and deforms the cell membrane. 
The polymerization has a domino effect, initiating a myriad of processes characterized 
by an inflammatory process, which in turn creates a complex sickling deluge.  This 
deluge includes the dehydration of the red blood cells, which in turn creates an 
irreversible sickling of the red blood cells, hemolysis which leads to anemia, and 
vasoconstriction caused by nitric oxide depletion. The outcome from these cyclical 
events is vaso-occlusion, which causes pain from the underlying ischemia related to the 
occlusions and also causes a depletion of oxygen from the tissues. This cascade of 
events can then lead to organ damage (Claster, 2003; Field, Knight-Perry, & Debaun, 
2009; Platt, Eckman, Beasley, & Miller, 2002).          
There are many contributing factors that may trigger a vaso-occlusive crisis pain 
episode, which include the following: physical and emotional stress, extreme 
temperature changes, infections, and dehydration. However, some vaso-occlusive crisis 
pain episodes may have no trigger or contributing factors: for example, some episodes 
occur during sleep, yet physical and emotional stress, extreme temperature changes, 
infections, and dehydration can also trigger vaso-occlusion while the individual is asleep 
(Aisiku et al., 2007; Benjamin, Swinson, & Nagel, 2000; Dunlop, 2006; Givens, 
Rutherford, Joshi, & Delaney, 2007). Vaso-occlusive crisis pain episodes can occur any 
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time of the day or night and are unpredictable by the potential for sudden onset and 
varying degrees of pain intensity as experienced by the individual. This is not to say that 
all episodes are spontaneous. There are some instances in which the onset of a pain 
crisis can be predicted by some individuals under certain circumstances (Newcombe, 
2002; Smith et al., 2008; Smith et al., 2005).  
Ballas (1995) indicated that acute sickle cell crisis pain episodes evolve over four 
distinctive phases: prodromal, initial, established, and resolving. The first phase, the 
prodromal phase, can last from one to four days and is characterized by pain, 
weakness, fatigue, and loss of appetite, with a possibility of respiratory symptoms or 
fever. The initial phase (actually the second phase of the four) can overlap with the 
prodromal phase and can last one to four days also, this phase is characterized by 
worsening pain, irreversibly sickled cells, dense red blood cells, increased hemoglobin 
distribution width (HDW), and increased red cell distribution width (RDW). The third 
phase, labelled as the established phase, can last from three to six days and is 
characterized by, possible leukocytosis, possible increased temperatures, increased 
reticulocyte counts, elevated lactate dehydrogenase, and possible increases in C - 
reactive protein and serum amyloid, with possible decrease in hemoglobin. The fourth 
phase, called the resolving phase, can last seven to ten days and is characterized by 
stabilized RDW and HDW, decrease in dense red blood cells, decrease in irreversibly 
sickled cells, possible increase in plasma viscosity, increase in platelet counts, with 
possible increase in fibrinogen, and erythrocyte sedimentation rates (Ballas, 1995 & 
Ballas, 2007). 
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Complications of Sickle Cell Disease 
The many complications of sickle cell disease (SCD) may be directly correlated 
to the effects of vaso-occlusive crisis pain episodes. Providers are most familiar with the 
hallmark symptom, which is vaso-occlusive crisis pain. The onset of multiple ischemic 
periods and the resulting occlusions force individuals with sickle cell disease to live with 
a plethora of conditions related to these phenomena, which include:  
 chronic pain 
  fatigue 
  Priapism 
  renal failure 
  pulmonary hypertension 
  hypertension 
 neuropathy 
 delayed growth and puberty 
 strokes 
 cholelithiasis 
 retinopathy 
 blindness 
 splenic sequestration 
 cardiomyopathy 
 bacterial infections 
 acute chest syndrome 
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 avascular necrosis 
 leg ulcers 
 aplastic episodes 
 depression 
 hepatic sequestration  
Often these individuals experience acute pain along with chronic pain-pain they 
experience daily and these occurrences can often overlap.  This makes it more difficult 
for patients, and providers to distinguish the difference between the chronic and the 
acute pain experienced during vaso-occlusive pain episodes (Ballas, 2010; Dunlop, 
2006; Field et al., 2009; Platt et al., 2002; Wang, 2007). In recent years, Hydroxyurea 
(HU) was approved for use in adults with SCD to increase the levels of their fetal 
hemoglobin. The increase in fetal hemoglobin has been associated with a decrease in 
the frequency of vaso-occlusive episodes, an improved mortality from acute chest 
syndrome, and a decreased need for chronic blood transfusions (Ballas et al., 2006; 
Steinberg et al., 2003).  
Mortality/Morbidity of Sickle Cell Disease 
There are many factors that affect the mortality and morbidity of the adult living 
with sickle cell disease. These include: type of SCD, age, baseline hemoglobin (Hgb) 
and white blood count (WBC), left ventricular function, left ventricular size, corrected QT 
(QTc), tricuspid regurgitant jet velocity (TRv), and pulmonary hypertension (pHTN), 
which is defined as TRv of at least 2.5m/sec (Fitzhugh et al., 2010). These factors often 
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influence the research and the discussions that compare patients with sickle cell 
disease and their incidence of death. 
Fitzhugh et al. (2010) studied a population of 240 adult sufferers of SCD in which 
43 of the subjects died during the study period. The median age for survival was 39 
years for females (95% CI: 34-56), 40 years for males (95% CI: 34-48), and 40 years 
overall (95% CI: 35-48). The causes of death were reported as follows: cardiac causes 
for death accounted for 25.6% (11/43 patients); pulmonary, 14% (6/43 patients); other 
SCD-related, 32.6% (14/43patients); unknown, 14% (6/43patients); and others 
accounted for 14% (6/43 patients). More specifically, the most common causes of death 
amongst the patients studied were found to be cardiac arrest, pulmonary emboli, multi-
organ failure, and stroke; additional research is required to determine the necessary 
treatments to prevent fatal cardiopulmonary complications (Fitzhugh et al., 2010). Other 
studies concurred that individuals living with SCD, as a group, experience a significantly 
shorter lifespan and have increasingly more disease-related complications that directly 
affect their mortality and morbidity, such as arthritis, diabetes, heart disease, chronic 
lung problems, and kidney disease (Ballas et al., 2006;  Fitzhugh et al., 2010; Steinberg 
et al., 2003). 
Despite the many medical advances of the last 30 years, there remains a higher-
than-average premature death rate for individuals living with sickle cell disease than 
those without sickle cell disease (Fitzhugh et al., 2010). Another study conducted by 
Ballas and Marcolina (2006), reported an average life expectancy of 45 years of age for 
individuals with SCD (Ballas et al., 2006). One possible explanation for this occurrence 
may be the inferred correlation between prolonged vaso-occlusive pain episodes and 
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poorly managed pain, which can lead to end-organ damage (Ballas et al., 2006; 
Fitzhugh et al., 2010; Steinberg et al., 2003). In recent years the cause of death and 
mortality in individuals living with sickle cell disease has shifted from infectious 
processes to cardiac or pulmonary complications (Ballas et al., 2006; Steinberg et al., 
2003; Fitzhugh et al., 2010). Although adults with SCD are prone to premature mortality 
and increased morbidity, for children ages 6 months to 5 years with SCD mortality and 
morbidity are directly correlated with decreased incidences of fatal infectious processes 
prior to the implementation of antibiotic therapy (Ballas et al., 2006; Frei-Jones et al., 
2008; Steinberg et al.,  2003). Further research of this nature could help tease out the 
determinants of decreasing mortality and morbidity rates in adults with SCD. 
Another aspect of morbidity/mortality to consider for discussion and additional 
research is the correlation between poorly managed vaso-occlusive crisis pain and 
organ damage. Organ damage occurs in individuals living with sickle cell disease as a 
direct result of the sickling process and damage from repeated crises (Ballas et al., 
2006; Eckman, 2010; Fitzhugh et al., 2010). Researchers need to examine barriers to 
the usage of Hydroxyurea (HU) among SCD patients in all age groups and the possible 
effects of limiting the number of vaso-occlusive pain crisis events on organ damage, 
mortality, and morbidity. As the research that was reviewed here suggests, patient 
engagement and participation is needed. Likewise, it is imperative for providers to 
encourage the use of HU medication to determine if less vaso-occlusive crisis leads to 
less organ damage and to determine future treatment options for individuals living with 
SCD. Such work has the potential to positively impact SCD patients by decreasing 
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mortality and morbidity across their lifespans (Ballas et al., 2006; Eckman, 2010; 
Fitzhugh et al., 2010; Steinberg et al., 2010).  
Utilization of Services 
People living with sickle cell disease utilize the emergency department, inpatient 
facilities, and medical offices to manage and treat acute symptoms of vaso-occlusive 
pain crisis episodes that can no longer be managed at home. Vaso-occlusive crisis pain 
episodes accounted for 94.6% of the hospital admissions for patients with sickle cell 
disease, which usually were from the emergency department (Epstein et al., 2006). Men 
represent a higher percentage of admissions than women for acute painful episodes 
(56.6% versus 38.1% of total admissions); for men, the admissions were directly related 
to acute painful crisis events, while women’s admissions tended to be non-crisis related 
(Ballas & Lusardi, 2005). It is important to note that SCD affects men, women, and 
children differently, and the responses for these individuals will be different depending 
on age, severity of disease, genotype, coping skills, and a myriad of other factors such 
as infection, acute chest syndrome, cardiomyopathy, and avascular necrosis. 
Ballas and Lusardi (2005) conducted a study over a five-year period, in which 
they reviewed the inpatient information and looked at several aspects of SCD 
admissions, such as the number of patients admitted for vaso-occlusive crisis pain 
episodes (a total of 136 patients admitted for 1,540 instances), and average length of 
stay (ALOS), which was 7.6 days with sickle SS (Ballas & Lusardi, 2005). Admissions 
other than vaso-occlusive episodes were for transfusion, surgery, complications of 
pregnancy, delivery, trauma, and hemodialysis. Additionally, 37 of the admissions with 
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acute vaso-occlusive episodes also had a diagnosis of acute chest syndrome (Ballas & 
Lusardi 2005). Acute chest syndrome was diagnosed in 64 of the patients after 
admission, with a total of 101 admissions (6.6% of all admissions) with acute chest 
syndrome as a diagnosis. Additional diagnoses identified during hospitalization of 
patients with acute vaso-occlusive episodes included infections, acute chest syndrome, 
cardiomyopathy, and priapism (Ballas & Lusardi, 2005).    
Epstein et al. (2006) reviewed 142 unique individuals’ medical records for a total 
of 4,874 emergency department (ED) visits, of which 1,607 (33%) resulted in a 
hospitalization, 3,267 (67%) were independent ED usage not requiring hospitalization.  
These 142 unique patients were engaged in continuous service for 3-5 years, meaning 
they received their hematological and primary care within this system. A total of 1,681 
inpatient admissions, which comprised 95.6% of the hospitalizations, originated from the 
ED (1,607/1,681). For the overall patient population studied, the means were 4.1 office 
visits per year, 7.4 total ED visits per year, 4.9 independent ED visits per year, 2.7 
inpatient admissions per year and 23.2 total bed days per year. The median ED usage 
was only 2.5 totals, and 1.0 independent visit per year. The median admission rate was 
only 1.6 admissions per year, which accounted for a median 12.8 total bed days per 
year. The average length of stay was 6.8 days, with a median of 5.9 days (Epstein et 
al., 2006). 
Interestingly, the main difference between the patient populations was the 
genotype of the sickle cell disease – homozygous sickle-S disease in the Ballas and 
Lusardi (2005) study, and hemoglobin sickle-C disease in the Epstein et al. (2006) 
study; however, the findings were very similar in nature.  Again, it is important to note 
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there were no references made to the national guideline for pain management (NHLBI, 
2002) in either of these studies. These studies reviewed the practice patterns of hospital 
inpatient and emergency department use and, described patterns of healthcare 
utilization and frequency of vaso-occlusive episode pain admissions, within large urban 
hospital settings (Ballas & Lusardi, 2005; Epstein et al., 2006).   
Ballas and Lusardi (2005) identified the primary cause of hospital admissions 
were for acute vaso-occlusive pain episodes. This study consisted of 136 individual 
patients with an observation admission rate of 1,540 admissions during the 5-year study 
period (Ballas & Lusardi, 2005).  Practice patterns for utilization that were observed 
included: 50% of the patients were readmitted within thirty days of discharge for vaso-
occlusive pain episode; 16% of all patient admissions were within 1 week of discharge 
which included a higher mortality rate associated with readmission and required careful 
monitoring (Ballas & Lusardi, 2005).  Causes for readmission were most frequently 
determined to be premature discharge, withdrawal symptoms, and new acute pain 
episodes (Ballas & Lusardi, 2005).  When examining this information, Ballas discovered 
several factors for readmission which included high pain scores in 52 of the patients 
readmitted (higher than days 7 and 8 of their previous admissions); suboptimal plan of 
pain management upon discharge (patients’ opioid dose at home much lower than 
hospital pain management causing either withdrawal or new acute pain episodes). 
During this 5-year study, 26 (36%) of the total number of included patients died. Of the 
readmitted patients, 20% died within 1 week of being hospitalized, while 14% of all 
sickle cell patients died within the 5-year study period (Ballas & Lusardi, 2005). It was 
noted during this 5-year period for adult patients with homozygous sickle-S disease and 
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hemoglobin sickle-C disease. The emergency department was a common place for 
utilization for all patients with sickle cell disease. Of these, there was a mean of 7.4 
visits per patient year, of which 1/3 of the patient visits resulted in hospital admission 
with the primary diagnosis of a vaso-occlusive crisis pain episode (Ballas & Lusardi, 
2005; Epstein et al., 2006). 
Pain scores were also evaluated as part of the equation for high re-admission 
rates within this patient population, with a reasonable explanation for this occurrence 
(Ballas & Lusardi, 2005). According to Ballas and Lusardi (2005), upon the first day of 
admission one would predict the pain score of the individual to be at its highest, and 
then decreasing during the ensuing inpatient hospital days, with a marked decrease in 
the intensity of pain from the vaso-occlusive episode from day 1 (admission) to day 5 of 
hospitalization. Regression analysis shows significant decrease in the pain score 
between day 1 and day 8 (r² = 69%, P = 0.011); the difference was even more 
significant between days 1 and 5 (r² = 94%, P = 0.007). Regression analysis between 
days 5 and 8 showed no significant difference (P = 0.106) (Ballas & Lusardi, 2005).  
Pain intensity scores upon admission averaged m= 8.7 ± 1.24 for n=348 
measurements of pain, with a range of pain scores being 6-10, and a median pain score 
of 9. Pain intensity scores at the time of discharge averaged m=6.6 ± 1.81 for n=348 
measurements of pain, with a range of pain scores being 2-10, and median pain score 
of 7 (Ballas & Lusardi, 2005). With each hospital day, pain intensity scores trended 
downward until day 4 (day 1: n= (337) m= 8.7 ±1.17 P= <0.001 1 vs. 2-8…, day 4: n= 
(264) m= 7.5 ±1.60 P= <0.025 4 vs. 5-8) (Ballas & Lusardi, 2005). Pain intensity scores 
from day 5 until the day of discharge indicated a plateau in pain and were not 
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considered statistically significant [Day 5: n= (240) m= 7.3 ± 1.69 NS 5 vs. 6-8] (Ballas & 
Lusardi, 2005). 
Several possible reasons for the moderate pain that many individuals may have 
been discharged experiencing included: 1. Difference in being admitted to hematology 
units and being managed by hematologist with interests in sickle cell disease. 2. 
Aggressive pain management.  3. Decision by the patient to leave due to family, job, or 
childcare issues.  4. Provider bias.  5. Insurance carrier rules and pressure for discharge 
(Ballas & Lusardi, 2005).  These are significant details that need to be addressed during 
sickle cell disease care management in the adult population as these issues are less 
prevalent in pediatrics.  
The lack of evidence continues to make the case for improvements in care that 
will lead to continuity and better quality when treating and managing patients during a 
vaso-occlusive crisis pain episode. Lastly, premature discharge from the hospital or 
suboptimal practice patterns of pain management upon discharge may result in 
readmissions, usually occurring within a week of discharge (Ballas & Lusardi, 2005). 
These studies agreed and implied the need to establish standards of care for 
hospitalized SCD patients with vaso-occlusive crises, with continued research needed. 
It has been suggested that personal resources may play a critical role for 
improving the health status and the quality of life for those individuals living with the 
chronic illness of sickle cell disease (Jenerette & Murdaugh, 2008). The discussion of 
health outcomes of adults with sickle cell disease, based on their individual ability to 
cope, adjust, advocate and participate in their care, is a feature that is certainly needed 
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in the navigation of this debilitating chronic illness. The lack of evidence in this area 
necessitates further testing and research to fill the gap in knowledge (Bediako et al., 
2007; Edwards, Telfair, Cecil, & Lenoci, 2001; Jenerette & Murdaugh, 2008). 
Along with the encouragement of active participation in care and treatment, the 
adult care providers must also consider what barriers exist in creating relationships that 
allow for mutual trust and respect of the provider and patient. Self-efficacy and self-
management needs to be encouraged and nurtured (Bediako et al., 2007; Edwards et 
al., 2001; Jenerette, & Murdaugh, 2008). Self-efficacy can be a primary variable in 
predicting disease symptomatology and health services utilization for adult patients with 
sickle cell disease (Edwards et al., 2001). Edwards et al. (2001) reported that lower self-
efficacy levels in adults coincide with more physical and psychological symptoms, more 
severe SCD pain, and more frequent physician visits. Previous studies on fibromyalgia 
and arthritis denote changes in self-efficacy that were more superior forecasters of 
outcomes than preliminary levels of efficacy beliefs (Edwards et al., 2001). Individuals 
with SCD who display higher levels of self-efficacy may also demonstrate higher levels 
of physical and psychological health and lower risk for poor SCD adjustment (Edwards 
et al., 2001). 
           Perceived stress and psychological symptoms were significantly associated with 
pain severity with r values of 0.35 and 0.34, respectively (Bediako et al., 2007). In a 
sample of African Americans, Bediako et al.’s (2007) study to some extent provided an 
exploratory model of the confluence of racial centrality, pain, psychological symptoms, 
and the correlations for pain episode frequency, and health care usage. Racial centrality 
as defined by Sellers (1998), “refers to the extent to which a person normatively defines 
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himself or herself with regard to race; centrality is relatively stable across situations” 
(Sellers et al., 1998). According to Bediako et al. (2007), racial centrality for the purpose 
of this study was defined as normative self-relevance of race. Study results determined 
that both stress and mood play a role in the course of SCD vaso-occlusive pain crisis 
episodes, and that stress may precipitate vaso-occlusive pain (Porter, Gil, Carson, 
Anthony, & Ready, 2000). Stress and mood was shown to be significantly associated 
with increases in same-day pain ratings. A significant number of painful episodes were 
preceded by increases in more severe stressors at least two days prior to onset, 
suggesting that stress may be a precipitating factor of SCD vaso-occlusive pain crisis 
episodes (Porter et al., 2000). Mood was assessed based on positive affect (PA) that 
entailed pleasant emotions like joy and happiness, while negative affect (NA) was 
associated with emotions like sadness and fear (Porter et al., 2000).  Mood was 
included in this study since there is mounting evidence which supports chronic illnesses 
impacts, pain, functional capacity and disease symptoms (Porter et al., 2000).  It is also 
suggested that more research should be conducted in this area (Porter et al., 2000). 
Average Length of Stay 
Certain chronic illnesses such as sickle cell disease have an “average” number 
of hospital days associated for care and treatment.  The national average for length of 
stay (ALOS) for an adult inpatient with vaso-occlusive crisis is 6.5 days. However, when 
the Regional Medical Center at Memphis (Tennessee) implemented an inpatient care 
delivery model for sickle cell disease patients, ALOS decreased from 5.8 days in 2002 
to 4.6 days in 2007 (Adams-Graves et al., 2008). The ALOS has been shown to be 
decreased by the introduction of the “Day Hospital Model” and treatment protocols 
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specific for the management of sickle cell disease care; these models have also created 
effective treatment measures and substantial cost savings (Adams-Graves, 2008; 
Jordan, 2008). Addressing clinical practice patterns deficits by implementing quality 
improvements identified with the guidance of the Dartmouth Microsystem can positively 
influence the ALOS. A possible reduction in the number of days away from an 
individual’s “normal life” is significant benefit to the person and family and can 
appreciably increase patient satisfaction.      
Financial Burden of Sickle Cell Disease 
An intriguing and important aspect of healthcare that should not be overlooked is 
the financial burden that chronic illness bears across the lifespan. When estimating the 
economic burden of illness from a health care system perspective, the Medicaid 
reimbursement rates are generally used as the proxy for the actual cost of care (Kauf, 
Coates, Huazhi, Mody-Patel, & Hartzema, 2009). It is difficult to estimate the overall 
cost of care for the adult SCD patient, in the case of employer-sponsored and non-
Medicaid patient populations.  
Kauf et al. (2009) in one study sample of 4,294 patients, aggregate health care 
costs usually rose with the age of the patient, from $892 to $2,562 per patient per month 
in the 0-9 and 50-64 year age groups, respectively. The average cost per patient-month 
was $1,389. Largely, 51.8% of care was directly related to SCD care issues; the 
preponderance of which (80.5%) was directly associated with inpatient hospitalizations 
(Kauf et al., 2009). Total lifetime healthcare costs can be estimated to reach as much as 
$953,640 for a SCD patient at age 45. The present value of lifetime costs is $460,151. 
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Median lifetime costs were estimated at $392,940 (Kauf et al., 2009). An important note 
is that the burden of care in different regions may vary, but Medicaid reimbursement 
remains consistent across the country.  
According to Kauf et al. (2009), the “costs of care estimates are important inputs 
to health care planning, research prioritization, and the economic evaluation of new 
SCD treatment strategies.” Several studies reiterated some very important topics 
regarding SCD. Some of these include sickle cell disease morbidity, which remains 
persistently high; the need for improved treatments; interventions designed to prevent 
complications; and avoidance of hospitalization; and reductions in the economic 
burdens of the disease (Ballas & Lusardi, 2005; Bediako et al., 2007; Epstein, Yuen, 
Riggio, Ballas, & Moleski, 2006; Frei-Jones et al., 2008; Kauf et al., 2009; Telfair et al., 
2003).  
Clinical Practice Guidelines and Protocols 
Several studies have addressed clinical practice pattern elements such as 
treatment protocols, and/or standardized care, reduction of hospital-associated costs, 
improvement of pain management as a direct effect of the standardization of care, 
reduction in length of stay, patient satisfaction, and the role of the family and health care 
providers for individuals that live with SCD (Adams-Graves, et al., 2008; Frei-Jones et 
al., 2009; Givens et al., 2007). One of the approaches to creating more effective 
treatment options and improved outcomes has been the development and 
implementation of the sickle cell, hospital day unit for the provision of care for adult SCD 
patients (Adams-Graves, et al., 2008).   
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One example of the benefits of treatment protocols and guidelines with the 
implementation of the sickle cell hospital model has been at Diggs-Kraus Sickle Cell 
Center in Memphis, Tennessee (MED). This facility provides services to 450 adults with 
SCD and receives an average of 2,000 visits per year. The MED serves an adult 
population that is comprised of 95% over the age of 21 years, with a female population 
of 53% (Adams-Graves et al., 2008). The ethnicity of this patient population is primarily 
African American, except for one patient of Hispanic descent. The chief medical 
requirements for admittance at the MED for individuals with SCD do not specify crisis 
pain as admission criteria.  
The results of creating and implementing the inpatient care model with the SCD 
unit triggered a reduction in the use of the emergency department, improved SCD care, 
and improved patient/family satisfaction (Adams-Graves et al., 2008). The 
implementation of standardized admission orders and guidelines for inpatient 
management and treatment, and the implementation of standardized treatment 
protocols for the emergency department care of individuals suffering from vaso-
occlusive crisis pain episodes all yielded the same kind of results for individuals at acute 
care facilities. Implementing the inpatient care model with the SCD unit had a positive 
outcome for the care of the sickle cell patients, which was indicated with a marked 
decrease in ED visits by sickle cell patients after implementation of pain management 
guidelines and increasingly proactive efforts by the Hematology Clinic to bring their 
patients back to the clinic and into sickle cell day hospitals (Adams-Graves et al., 2008; 
Givens et al., 2007). Total hospital visits did not change significantly in any of the 4 
years, (p>0.10) under comparison. Total ED visits decreased significantly over the 4-
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year period (p<0.001), whereas clinic visits steadily increased (p<0.001). Return visits to 
the ED within 30 days also declined significantly (p<0.001) (Givens et al., 2007). Also, 
the number of admissions per year and the total admissions per hospital visit declined 
markedly over time in both studies. However, the total hospital admissions did not 
change, but the proportion of ED visits that resulted in admission in year 1 (29%) was 
significantly lower than the proportion admitted in year 2 (43%), p=0.04. Two major 
causes for this change were that (a) the use of pain protocol using morphine or 
hydromorphone coupled with (b) increased access to outpatient clinics decreased ED 
visits, hospitalization, and also the increased utilization of a more stable primary care 
clinic setting by patients with SCD (Adams-Graves et al., 2008; Givens et al., 2007). 
These results demonstrate the need to continue research for improving clinical 
practice and management of vaso-occlusive pain episodes of SCD.  This further 
stresses the importance and the need for high-quality sickle cell care and management 
in inpatient and outpatient settings, both of which can enhance the quality of care, 
decrease hospital-associated cost, and improve acute pain management of patients 
(Adams-Graves et al., 2008; Frei-Jones et al., 2009; Givens et al., 2007). It is critical for 
researchers to further explore clinical practice patterns and the impact for SCD on the 
quality of pain management for all patients with chronic or recurrent pain, patient 
perception of ED pain management and the relationship of non-emergency sources of 
care (Givens et al., 2007). 
Rees (2003) recommended a written protocol for patients admitted for vaso-
occlusive episode, with a multidisciplinary approach to management.  According to 
Rees, (2003) the following is recommended: 
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 Sickle cell trait is not likely to cause pain and should not be considered the 
source of pain. 
 Identification cards with individualized treatment requirements and 
baseline information should be issued to sickle cell disease patients. 
 Nitrous oxides can be administered while being treated in the ambulance 
not to be used frequently or for more than 1 hour. 
  Pain medications should be administered within 30 minutes of “entering 
the hospital”, with effective analgesia within 60 minutes. 
 Assessments of pain, respiratory rate and sedation should be assessed 
“every 20minutes until pain is controlled”. 
 This recommendation also strongly states that Demerol/Meperidine should 
not be administered for pain control in SCD patients. 
         The National Institute for Health and Clinical Excellence (NICE, 2012) created 
guidelines for the management of acute painful sickle cell episodes while hospitalized 
for the individual with vaso-occlusive pain episode across the lifespan which included, 
children, adolescents, and pregnant women. This guideline was created to help 
decrease the variability in care for the United Kingdom, and education for optimal 
management.   The recommendations included: 
 Patient centered care. 
 Individualized assessments-treat the pain event as a medical emergency, 
ascertain which treatments worked for previous episodes, listen to the 
patient. 
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 Assess pain and offer analgesia within 30 minutes of presentation at 
hospital. 
 Assess and monitor blood pressure, oxygen saturation, pulse rate, and 
temperature. 
 Properly administer medications which include opioids, and adjuvants 
 Frequent and ongoing assessments every 30minutes initially and at least 
every 4 hours once pain relief has been achieved. 
 Consider acute complications: abnormal respiratory signs and symptoms, 
chest pain, fever, infection, and hypoxia. 
 Do not administer Demerol/Meperidine. 
 Healthcare professionals should receive ongoing training, topics should 
include: pain relief, identifying complications, and attitude and presumptions 
regarding patients presenting in acute sickle cell pain. 
The NICE guidelines (2012) did not make medication recommendations for the 
treatment of vaso-occlusive pain for each area has locally agreed protocols that should 
be followed which do included opioids, and adjuvants.   
The NHLBI guideline recommendations are an important aspect of care for the 
individual experiencing a vaso-occlusive crisis pain episode.  The current NHLBI (2002) 
emergency treatment of acute pain episode guidelines state:    
Patients should undergo a thorough history and physical examination to 
determine whether an illness might have precipitated the pain, so that the 
cause and symptom can be treated simultaneously. Patients should be 
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seen immediately by a physician if they experience severe abdominal 
pain, recurrent vomiting, respiratory symptoms, neurologic signs of paresis 
or paralysis, acute joint swelling, priapism, or abrupt fall in hemoglobin. 
Superimposition of acute pain on chronic pain may confound assessment 
and treatment.  
All patients should undergo rapid assessment with frequent reassessments for 
acute pain episode. Pain management should be aggressive to relieve pain and achieve 
maximum function expediently. Severe pain in SCD should be considered a medical 
emergency which therefore needs prompt and timely treatment. The 2002 NHLBI 
guidelines make the following recommendations for treatment: 
1. Begin hydration: the initial fluid should be 5% dextrose + half-normal saline with 
20 mEq KCL/L adjusted for serum chemistries.  
2. Assess the cause of pain and any complications. Determine medications or 
treatments taken at home, including usual drugs and dosages, and any potential 
side effects during acute pain. Then use the opioid dosage which provided 
adequate analgesia at a previous time engaged in care (for the patients known to 
a practice with a previous treatment history).  
3. Avoid intramuscular injections. However, if unable to obtain intravenous access, 
the subcutaneous route for administration of opioids is effective and acceptable.  
4. Frequent assessments of pain intensity, relief, mood, and sedation level are 
required every 15 to 30 minutes after each dose of medication. 
5. Titration to relief is an important aspect of care, regarding the nature of recurrent 
pain episodes and for consistent management of acute pain episodes. Titration 
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can be achieved with aggressive dosing and with frequent or close monitoring; 
bolus dosing should be set at timed intervals after a loading dose, or “by the 
clock” (BTC) dosing, such as morphine 4 mg every 2 hours.  
6. Disposition at the conclusion of treatment must also be considered, whether an 
individual is being discharged from the ED or from the inpatient setting.  
Individuals need prescriptions for equivalent doses of pain medication to maintain 
pain relief. However, after aggressive treatment is given and pain relief is not 
achieved, inpatient admission should be considered (NHLBI, 2002). 
Provider Knowledge 
It has been acknowledged that the education of the health care providers is 
pivotal to the success of any practice change, especially in a cohort of patients that are 
deemed “chronic” or high utilizers of care (Aisiku et al., 2007; Fitzhugh et al., 2010). 
There is a serious gap in the knowledge base of the providers in the area of treatment 
and management of the adult in vaso-occlusive pain crisis episodes; this can certainly 
be a topic for future studies, since this gap in knowledge may further prevent providers 
from more rapidly responding to patients’ requests for changes to treatments and 
medication regimens (Adams-Graves et al., 2008; Ballas & Lusardi, 2005; Aisiku et al., 
2009; Epstein et al., 2006). Studies have shown that individuals who are in a vaso-
occlusive pain crisis episode and treated in a sickle-cell specific care center have higher 
patient satisfaction scores, more aggressive treatment, and improved overall pain 
management when compared to individuals who receive care in non-specific treatment 
centers (Adams-Graves et al., 2008; Aisiku et al., 2007; Ballas, 2010; Benjamin et al., 
2000; Field et al., 2009; Givens et al., 2007; Haywood et al., 2009; Smith et al., 2005).       
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Solomon (2008) found that treatment and management of vaso-occlusive pain 
crisis episodes in SCD patients were not given much attention in medical training 
materials, with specific management recommendations in only “4 of 19 medical 
textbooks."  This study further reiterated information from similar research conducted by 
Smith et al. (2005) and Benjamin et al. (2000); namely, providers of care for SCD vary 
greatly in their knowledge of SCD in general and of opioid usage. They also frequently 
possess possible prejudicial barriers and predetermined judgments regarding “drug-
seeking” behaviors of individuals with sickle cell disease in vaso-occlusive pain crisis 
episodes, deeming these patients to be “frequent flyers” or “needing a fix” (Adams-
Graves et al., 2008; Ballas, 2010; Benjamin et al., 2000; Smith et al., 2005; Solomon, 
2008; Jordan, 2008). The pain of SCD is real and requires non-prejudicial and engaged 
care providers to manage the symptomology and pain manifestations of this disease. 
Studies have shown that when SCD care providers are trained to manage the health 
issue, patient satisfaction and outcomes are improved – “practice makes for improved 
care” (Jordan, 2008; Adams-Graves et al., 2008; Ballas, 2010; Benjamin et al., 2000; 
Aisiku et al., 2007). 
Clinical Practice Patterns for Treatment 
Significant differences exist in the care of children and adults in vaso-occlusive 
pain crisis episodes. One difference for children is that the barrier of mistrust does not 
yet exist (Field et al., 2009; Jenerette & Murdaugh, 2008). Drug-seeking behaviors, 
although they may exist in pediatric populations, are not treated in the same manner as 
adults; the children are assessed for adequate pain management and treated 
accordingly. This approach is not always extended to the adult population, where 
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mistrust and judgmental care can be evident (Aisiku et al., 2007; Ballas, 2010; Ballas & 
Lusardi, 2005; Givens et al., 2007).  
The implementation of standardized sickle cell treatment guidelines and 
protocols suggests these clinical practice recommendations may be cost saving in 
nature, while reducing hospital readmission in the same population (sickle cell disease), 
with patient-focused quality measures such as: reduction in pain score upon discharge, 
and reduction in complications associated with admission for pain (Ballas & Lusardi, 
2005; Epstein et al., 2006; Frei-Jones et al., 2009). During the evaluation of the 
utilization of guidelines that were implemented overall, pain management was improved, 
and admissions were decreased or made significantly shorter in a few limited practice 
locations (Frei-Jones et al., 2008; Frei-Jones et al., 2009). These practice guidelines 
allowed for more aggressive treatment in the emergency department, which had a 
tremendous impact on the admission and readmission rate of individuals seeking 
treatment for vaso-occlusive pain crisis episodes. During these studies, the patients in 
the ED received treatment in a timelier fashion, and had more adequate pain 
management, for example, adequate opioid dosing and use, decreased times for dose 
administration, longer time with the clinician for treatment and assessment (Ballas & 
Lusardi, 2005; Epstein et al., 2006; Givens et al., 2007; Frei-Jones et al., 2008; Frei-
Jones et al., 2009).  
In clinical practice patterns for children in vaso-occlusive crisis pain episodes with 
standardized guidelines, similar patterns of utilization have been assessed by using 
pediatric measures rather than adult measures. The participants’ pain was assessed by 
the ED physician and/or the hematologist using the standard scale for children, which is 
36 
 
the 0 to 5 Wong-Baker FACES scale; they rarely used the scale of 0 to 10 with children. 
Other differences included the number of morphine doses received, and child’s/parent’s 
comfort level (Frei-Jones et al., 2008). Patients, for whom the protocols were used, 
received more doses of morphine, with significantly improved pain relief than those 
individual patients with whom the protocol was not used (Frei-Jones et al., 2008).  As 
several studies have noted, suboptimal pain relief is addressed as an issue that needs 
further investigation for the improvement of pain management for individuals who suffer 
from vaso-occlusive pain episodes (Ballas & Lusardi, 2005; Epstein et al., 2006; Frei-
Jones et al., 2008).  
     Studies dealing with adult inpatients in settings with clinical practice guidelines or 
protocols in place versus patients that had their treatment in a general facility or a 
facility that did not have clinical practice guidelines to follow had similar findings to the 
previous pediatric study described (Adams-Graves et al., 2008; Aisiku et al., 2007; 
Givens et al., 2007; Frei-Jones et al., 2009). Namely, patients and providers were more 
satisfied with care, opioid dosing was more appropriate which improved analgesia, 
medications were given in a timely fashion, and attitudes of the providers were better 
concerning potentially “drug-seeking” behaviors that were often otherwise dismissed in 
non-specific treatment centers (Adams-Graves et al., 2008; Aisiku et al., 2007; Frei-
Jones et al., 2009; Givens et al., 2007; Jordan, 2008; Smith et al., 2005).  A 
collaborative team approach between generalists/hospitalists, continuity of care (same 
provider or provider team) during and post hospitalization, and planning for care or 
establishing a plan of care ought to be considered to improve the overall management 
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of the sickle cell patient in vaso-occlusive crisis pain episodes (Ballas & Lusardi, 2005; 
Epstein et al., 2006).  
Summary of Chapter 
          A methodical review of the literature was completed to ascertain information 
regarding utilization and impact of clinical practice guidelines in relation to the 
management of hospitalized adults with sickle cell disease in vaso-occlusive crisis pain.  
The research that is available is specific to either children or to the emergency 
department management of adults.  There is very little literature specific to the adult 
inpatient population for the management and treatment of vaso-occlusive crisis pain 
episodes. The minimal literature made references to improving the timeliness of 
initiation of care, administering appropriate and adequate analgesia, which could 
improve SCD vaso-occlusive crisis pain management, patient satisfaction, and 
reduction in the number of inpatient hospital days. One of the most important 
commonalities of the research was that when treatment guidelines, protocols, or 
treatment plans were in place, the overall care and management of the patient suffering 
from vaso-occlusive crisis episode pain showed general improvement compared to care 
received in non-specific treatment facilities or from providers whose mistrust issues 
could negatively impact clinical practice (Adams-Graves, P., Ostric, E. J., Martin, M., 
Richardson, P., & Lewis Jr, J. B.,2008; Ballas & Marcolina, 2006; Givens et al., 2007).  
  However, the protocols that have been identified in the literature did not focus 
on the first twenty-four hours of admission, a critical timeframe for the resolution of 
severe pain from a vaso-occlusive crisis pain episode.  In addition, a specialized 
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treatment protocol identified in an SCD specific facility is not available for replication in 
other treatment facilities, and has not been published in the literature/research to date.  
This quality improvement project addressed these gaps by comparing the current 
clinical practice patterns for vaso-occlusive crisis pain management and treatment to 
the NHLBI guidelines to identify optimal clinical practice patterns for the first 24 hours of 
care for the hospitalized adult. Once the clinical practice deficits were identified, the 
results were utilized to develop the clinical dashboard. The clinical dashboard will be 
used to monitor the measures or outcomes that have been recommended for 
performance and quality improvement, and will be evaluated prospectively, to improve 
the quality of clinical practices and create change that will optimize the highest quality 
evidenced based practice for the adult experiencing vaso-occlusive crisis pain.   
The critical review of existing literature was greatly needed to help identify the 
current clinical practices. The lack of research in the adult sickle cell population makes 
the determination of deficits for improving the quality of care paramount for creating 
evidenced based practices to guide high quality sickle cell care. The literature review 
provided the foundation for this project.     
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Chapter 3 
Methods 
Design  
This was a quality improvement project that utilized a retrospective medical 
record review to compare current clinical practice patterns during the first 24 hours of 
inpatient and the first 24 hours of observation status care for adults admitted with a 
sickle cell pain episode to current guidelines of the NHLBI for emergency department 
care utilizing the Dartmouth Microsystem quality improvement initiatives. This quality 
improvement project focused on data from the treatment provided within the initial 24 
hours of patient hospitalization in regards to patient assessments, utilization of 
intravenous fluids, oxygen administration, choice of pain medications including opioids, 
NSAIDS and other adjuvants medications. This QI project identified clinical practice 
patterns for adults hospitalized or on observation status for sickle cell pain and 
compared the practice patterns to the NHLBI guidelines.    
Setting and Sample 
This quality improvement project was conducted at a suburban university health 
center. The facility is a 225-bed facility in central Connecticut that provides general 
acute care services and is a prominent teaching hospital in New England.  Prior to this 
project, a historic review of the utilization data was completed looking at the time period  
from 4/1/2012-3/30/2014.  There were 219 vaso-occlusive crisis admissions from 
4/1/2012 through 3/30/2013 for 1988 inpatient days with an ALOS of 9.07 days, and 209 
admissions from 4/1/2013 through 3/30/2014 with 974 inpatient days with ALOS of 4.66 
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days (Utilization Data, 2014). In October of 2012, the facility’s Comprehensive Adult 
Sickle Cell Program acquired a full team of providers to treat and manage the sickle cell 
patients. The team included a full-time nurse practitioner, a full time social worker, along 
with the full time registered nurse that had been with the program starting the previous 
year.  This enabled comprehensive care and full engagement of the team in- and 
outpatient care settings with the adult sickle cell patients. The Sickle Cell 
Comprehensive Care Center facility offers many services which include diagnosis of 
sickle cell disease, ongoing ambulatory care and treatment, same day episode pain 
management, and many other services all related to the management of sickle cell 
disease.  
The data source was a convenience sample of medical records for adults 
admitted to the inpatient units for a vaso-occlusive crisis pain episode in the facility 
during a 12-month period (January 2014-December 2014). All were ages 18 years and 
older with confirmed sickle cell disease with one of the following variants: SS, SC, β+, or 
βº.  For the purposes of this project, the medical records were used to verify 
documentation of disease with hemoglobin electrophoresis or other similar test results 
for sickle S disease, sickle C disease, and sickle Thalassemia. The medical record of 
the admitted adult had a primary or secondary diagnosis of acute vaso-occlusive pain 
episode which required inpatient treatment or observation status for the management of 
the pain episode.  
All admissions were counted regardless of the number of admissions during the 
one-year time period for each patient. These inpatient admissions and observation 
status admissions occurred through the emergency department or direct admission. For 
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the purpose of this quality improvement project, the first 24 hours of inpatient admission 
was defined as the time from the patient’s documented arrival to the inpatient unit and 
the proceeding 24 hours after arrival. Likewise, for the purpose of this quality 
improvement project, the first 24 hours of observation status admission was defined as 
the time of the patient’s documented arrival to the inpatient unit and the proceeding 24 
hours after arrival, unless that admission was changed to inpatient within the 24-hour 
timeframe. The following medical records were excluded from this project: individuals 
who were younger than 18 years of age and/or patients’ whose admission records did 
not indicate acute sickle cell pain as the primary or secondary diagnosis. 
Project Instrument  
Sickle Cell Audit Record Data Sheet (SCARDS) 
The medical record abstraction form for sickle cell disease called the Sickle Cell 
Audit Record Data Sheet (SCARDS - Appendix A) was created by the student 
investigator.  The SCARDS form is a compilation of information based on an Excel 
spreadsheet that was used to collect information from the medical record during data 
abstraction. The data collected for this project included: age, race, gender, marital 
status, disease genotype, admission date and time, discharge date and time, primary 
and secondary diagnosis, frequency of vital signs, including pulse oximetry and weight 
(if recorded), use of oxygen (including amount and the apparatus such as nasal 
cannula, oxygen mask, and/or nebulizer equipment) when pulse oximetry <96% (to 
prevent further sickling and provide an oxygen rich environment  to decrease pain 
intensity by improving the ability of red blood cells to profuse tissues), frequency of 
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assessments (as recorded in the medical record), pain intensity and timing of each 
assessment, frequency of titrations (timing in relation to pain intensity score), 
administration of intravenous fluids (type, rate, potassium repletion and 
dosage/volume), use of opioid medications (dosage, frequency, and route of 
administration: IV, SQ or via PCA), use of adjuvant medications (medication, dosage, 
route, frequency and timing of the medication), home medications,  oral intake, output, 
allergies, and admission status of inpatient or observation. 
Procedure 
Institutional Review Board (IRB) approval was obtained from the hospital to 
conduct this study. The quality improvement project utilized the Dartmouth Microsystem 
quality improvement initiatives:  
1. Collected data to determine and compare the current clinical practice patterns 
of care for adults with SCD during the first 24 hours of inpatient admission 
with the NHLBI emergency department guidelines which give initial 
recommendations for inpatient management.  
2. Collected data to determine and compare the current clinical practice patterns 
of care for adults with SCD during the first 24 hours of observation status 
admission with the NHLBI emergency department guidelines which give initial 
recommendations for inpatient management.  
3. Analyzed the data collected to determine clinical practice pattern deficits  
      based on the NHLBI emergency department guidelines.           
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         Following IRB approval, the student co-investigator formally requested a list of 
patients admitted for vaso-occlusive crisis treatment during the study period. The patient 
list was password-protected and secured on a password-protected and/or encrypted 
device.  Patient names were randomly ordered and assigned a unique identifier to 
increase protection of patient identification.  After randomization for the patient list each 
medical record that was accessed was assigned an identifier for data collection for 
example 01. The protected information was used to complete the medical record review 
and data abstraction. The data sources for the retrospective medical record review were 
the medical records of identified adults with SCD admitted to the hospital for either 
inpatient or observation status care. Specifically, data extraction was for information 
regarding the patients’ treatment for the first 24 hours of their hospitalization once 
arrived to the inpatient unit regardless of admission status. The outpatient medical 
record was reviewed for data not available during hospitalization including hemoglobin 
genotype. 
         The timespan for data abstraction for each inpatient and observation status 
admission was January 1, 2014 through December 31, 2014. The data abstraction form 
developed by the student investigator contained the variables of interest that were 
utilized to collect the data. Each inpatient or observation status admission was given a 
unique sequential number identifier, such as 01, which assured patient anonymity and 
de-identified data.  
The completed de-identified data abstraction forms were stored securely on an 
encrypted computer and an encrypted USB storage device whereby both the student 
investigator and the major advisor had access to readily retrieve the stored information. 
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The student co-investigator completed all data abstraction. Upon completion of data 
collection from the medical records, the data were analyzed by imputing the collected 
information into the statistical program SPSS. The retrospective medical record data 
abstraction was based on the following variables, as recommended by the NHLBI 
guidelines: 
 Assessment and frequent reassessment of pain in a SCD vaso-occlusive 
crisis pain episode (pain score, timing).   
 Intravenous fluids (type/rate) and potassium repletion (if indicated), 
determined by intake data.    
 Use of supplemental oxygen for 92-95% pulse oximetry measurements 
that were recorded in the medical record as part of the completed vital 
signs.  
 Opioids and adjuvant medications (medication, dose, route, and 
frequency).   
The following data were collected on paper using the SCARDS sheets: age, 
gender, genotype, primary diagnosis, secondary diagnosis, vital signs frequency 
including pulse oximetry measurements, intravenous access type or subcutaneous 
access for the administration of medications and fluids, intravenous fluids and 
medications being administered, medications administered for the first 24 hours of the 
inpatient admission and observation status admission, supplemental oxygen use, and 
date of admission and date of discharge. Data was inputted in the SPSS data file and 
reviewed by the student co-investigator for inaccurate entries, typographical errors, and 
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incorrect characters. Data documented on paper were stored in a locked file cabinet in 
the student co-investigators office at the hospital with access only by the student 
investigator and major advisor. This information was maintained until completion of the 
quality improvement project and will be destroyed in five years from completion of the 
project.  
Data safety was maintained throughout the study by the student investigator, by 
implementing the following procedures: 
 All data for were collected and entered by the student co-investigator. 
 Data collection sheets were locked in a cabinet until the completion of the quality 
improvement project. 
 All data were imported directly into SPSS for analysis at the completion of 
collection.  
Analysis 
This quality improvement project was designed to serve as baseline information 
for the enhancement of current clinical practices for the hospitalized adult with a sickle 
cell vaso-occlusive pain episode as recommended by the NHLBI clinical guidelines.  
Descriptive statistics were used to analyze the data collected from the medical 
record chart abstraction. The demographic information from the medical records 
included frequencies for nominal and ordinal level measures and frequencies, means, 
and standard deviations for interval and higher level measures.  The study variables 
listed  for determining current clinical practices were also analyzed by the same 
process:  primary diagnosis, secondary diagnosis, vital sign frequency, intravenous 
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access, intravenous fluids, opioid medications administered, adjuvant medications 
administered for the first twenty-four hours of the admission and observation status, the 
use of oxygen for pulse oximetry of <96%, genotype, and frequency of assessment and 
reassessments were compared to the  NHLBI clinical guidelines to identify practice 
gaps. 
A clinical dashboard was created for the quality improvement measures 
recommendations after the completion of the data analysis. The clinical dashboard has 
become the tool used to measure in a systematic and ongoing method the outcomes 
deemed relevant to improve the overall quality of care to close the practice gaps during 
the first 24 hours of the inpatient and observation status admissions. This dashboard 
was created and presented to administrative leadership (nursing and medical) which 
provided consensus for quality improvement. 
Summary 
In conclusion, this quality improvement project involved a retrospective chart 
review covering a time span of 12 months at an academic suburban hospital site. The 
abstracted information was used to compare clinical practices regarding the treatment 
and management of the adult sickle cell patient in a vaso-occlusive pain crisis episode 
while hospitalized to the national guidelines for emergency department treatment 
published by the NHLBI. This quality improvement project sought information to 
determine current clinical practice deficits and the institutional patterns to bring them in 
line during the initial 24 hours of inpatient admission and the initial 24 hours of the 
observation status admission of SCD pain events.  This helped to define which clinical 
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practice changes were needed to improve the overall care and management of the adult 
hospitalized for a vaso-occlusive crisis pain episodes. This study provided the 
necessary data for future practice and research regarding inpatient management of the 
adult sickle cell patient.   
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Chapter Four 
Results    
          This chapter provides the results of the quality improvement project that utilized 
a   retrospective medical record review. This was a comparison of current clinical 
practice patterns during the first 24 hours of inpatient and the first 24 hours of 
observation status care for adults admitted with a sickle cell pain episode to current 
guidelines of the NHLBI for emergency department care utilizing the Dartmouth 
Microsystem quality improvement initiatives. The data presented here described the 
inpatient status medical records reviewed first, followed by a description of the 
observation status medical records data.  
Eligible Medical Records 
     The total number of medical records reviewed for this post-hoc analysis was 234 
records from the study period covering January 1, 2014 through December 31, 2014. 
Of 234 records both inpatient/outpatient observation encounters 66 records were 
excluded from this study as they did not meet the criteria of either primary or secondary 
diagnosis of vaso-occlusive crisis pain. There were 117 eligible inpatient encounters for 
project inclusion, and 51 outpatient observation encounters eligible for project 
inclusion, which were reviewed.   For the 117-inpatient encounter admissions, 112 
were admissions to the Oncology Unit, 4 were admissions to the Medicine Unit, with 1 
admission to the Multi-Specialty Unit. For the 51 observation encounter admissions, 
forty-seven were admitted to the Oncology Unit, and the other four encounters were 
admitted to the Medicine Unit.  
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Demographics 
    The age of the individuals in the sample (N=54) ranged from 21 to 56 years of age. 
The mean age was 31.08 (SD ± 9.48) years of age. Of these 54-unique medical 
records n = 23 (42.6 %) were male and n=31 (57.4%) were female. A total of n=48 
(88.9%) were Black or African American, n=5 (9.3%) were Hispanic/Latino, n=1 (1.9%) 
was Caucasian or White. Additionally, the marital status and genotypes are displayed 
for these individuals in Table 2.   
     Vital signs were reviewed for 168 individual encounters. 164 encounters (97.6%) 
had vital signs at least every four hours as recommended by the NHLBI 2002 
guidelines.   An important additional assessment usually associated with vital signs 
measurements included assessments for oxygen saturation rates or pulse oximetry 
levels. Pulse oximetry measurements were recorded for 117-inpatient encounters. The 
ranges for these measurements were 92% oxygenation to 100% oxygenation and are 
described in Table 3. There was one record with undocumented data. For fifty-one 
recorded pulse oximetry measurements for observation encounters with the range of 
90% oxygenation to 100% oxygenation are also described in Table 3. Table 3 contains 
the descriptive characteristics of the recorded pulse oximetry levels.  Continuous 
capnography for oxygenation was a requirement when individuals were treated with 
continuous or basal rate dosing of an opioid.  
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Table 2.   
Demographic Information (n=54)   
Demographics n Percentage 
Gender  
Male 
Female 
 
23 
31 
 
42.6% 
57.4% 
Race 
African American 
White 
Hispanics 
 
48 
1 
5 
 
88.9% 
1.9% 
9.3% 
Marital Status 
Single 
Married 
 
45 
       5 
 
83.3% 
9.3% 
            Divorced                                   4              7.4% 
 
    Genotype              
 HgSS                                      38                70.4%  
 HgSC                                      10             18.5%          
 HgSB+                                      6   11.1%     
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Table 3.  
Pulse Oximetry Measurements (N = 168)                                                                                                                                           
Inpatient Oximetry (n=117)                              Observation Oximetry (n=51) 
Measurements          n         %                  Measurements            n         %____________    
90                               0          0                         90                         1         2.0% 
92                               2        1.7%                     92                         1         2.0% 
93                               6        5.2%                     93                         1         2.0% 
94                               8        6.9%                     94                         3         5.9% 
95                               9        7.8%                     95                         2         3.9% 
96                               9        7.8%                     96                         4         7.8% 
97                             14        12.1%                   97                         6       11.8% 
98                             19       16.2%                    98                         9       17.6% 
99                              22      19.0%                    99                       15       29.4% 
100                            27       23.3%                 100                         9       17.6% 
No documented data  1         0.9%__________________________________________    
 
Pain                                           
     The assessment and evaluation of pain was a crucial element for this quality 
improvement project. The mean pain intensity level measured over the first 24 hours of 
the inpatient admission was 7.48 with (SD±1.89). For the pain intensity of the inpatient 
encounters there was one medical record noted to be missing and one medical record 
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was noted to be missing for the observation encounters. There were 51 observation 
encounters reviewed for pain intensity scores with the same measurement scale as the 
inpatient encounters. The mean pain intensity level for the observation encounters was 
7.92 with (SD ± 1.48).  
Table 4.   
Pain Intensity Scores   
              Inpatient                                                                   Observation 
Pain Intensity Scores           n      Percentage    Pain Intensity Scores    n     Percentage 
                  0                          1           0.9                             0                   0              0.0 
                  1                          0           0.0                             1                   0              0.0 
        2                          0            0.0                            2                   0              0.0 
                  3                          1           0.9                             3                   0              0.0 
                  4                          5           4.3                             4                   0              0.0 
                  5                          9           7.8                             5                   4              8.0 
                  6                         20         17.2                            6                   6            12.0 
                  7                         17         14.7                            7                   6            12.0 
                  8                         26         22.3                            8                 16            32.0 
                  9                         17         14.7                            9                 10            20.0 
                10                         20         17.2                           10                  8            16.0 
   No documented scores      1                                                                  1_________              
                                          
    Patient-reported acceptable levels of pain were also reviewed separately and were 
abstracted from the medical record as “yes” and “no” responses. More than half of all 
patients, regardless of hospitalization status, needed further intervention.  Of 117 
medical records reviewed for inpatient encounters only 28 (23.9%) had recorded 
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values; the observation encounters totaling 51 had 7 (14.0%) with recorded values with 
one undocumented data record.  
     Patient reported pain goals were recorded as part of the pain management 
assessment for both the inpatient and observation encounters. The mean patient 
reported pain goal for the inpatient encounters for 117 medical records reviewed was 
3.0 with (SD± 2.19). The inpatient encounters had 61 (52.1%) records without data 
recorded.  The observation encounters for 51 medical records reviewed had a mean 
patient reported pain goal of 2.5 with (SD± 2.37), with 31 records (60.8%) without data 
recorded. Please refer to Table 5 for the descriptive characteristics described.  
Table 5.  
Patient Pain Goals 
Inpatient (n=56)                                               Observation (n=20) _______________         
Patient Desired Pain Goal                           Patient Desired Pain Goal 
Pain Goal          n      Percentage_______ Pain Goal          n         Percentage_______ 
       0               15         26.8                               0                 8                 40.0 
       2                 2          3.6                                2                 2                 10.0 
       3               15         26.8                               3                 2                 10.0 
       4               11        19.6                                4                 5                 25.0 
       5                3           5.4                                5                 0                    0 
       6                8          14.3                               6                 2                 10.0 
       7                2           3.6                                7                 1                  5.0 
Note. Data was not documented for n = 61 inpatient and 31 observation patient stays.   
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Medical Interventions: 
     The administration of oxygen was seen more often in use in clinical practice than 
pulse oximetry based NHLBI, 2002 recommendations for indicated use with the 
reference range of 92-95% for supplemental oxygen. Of the 117 inpatient medical 
records reviewed n=56 (47.9%) reported the use of oxygen. Of the 51-observation 
status, medical records reviewed n=20 (39.2%) reported the use of oxygen.  
     The management of vaso-occlusive pain episodes required the use of intravenous 
fluids for hydration and to decrease viscosity of sickling blood, which is part of the 
pathophysiology of a vaso-occlusive pain episode. There are many different types of 
intravenous fluids readily available for administration during medical care. For the 
euvolemic patient the goal of maintaining homeostasis dictates the intravenous fluid to 
be administered. The NHLBI 2002, recommends the sickle cell patient be given as “the 
initial fluid 5 percent dextrose and half-normal saline”.  The most commonly 
administered intravenous fluids used in clinical practice during the first 24 hours of 
inpatient and the first 24 hours of observation status care for adults admitted with a 
sickle cell pain episode to current guidelines of the NHLBI were noted here.  
     Per the NHLBI recommendations the IVF of choice was D5 NS 0.45% which as 
described here was underutilized in both inpatient and observation encounters.  There 
was a total of 6 encounters in which no IVF was administered; the medical records did 
not indicate why fluids were not administered as recommended by the NHLBI, 2002. 
The three most commonly used intravenous fluids administered are described here in 
Table 6. 
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Table 6.  
Intravenous Fluids   
IVFs (Inpatient)        n            %             IVFs (Observation)                    n_       %    ___   
D5 NS 0.45%             46         40.0                    D5 NS 0.45%                 21        44.7 
NS 0.9%                    19          16.5                    NS 0.9%                          7        14.9 
NS 0.45%                  50          43.5                    NS 0.45%                      19        40.4 
No documented data   2          ____________No documented data          4          ___           
 
   For the 117-inpatient encounter, medical records reviewed the mean intravenous 
fluid (IVF) rate was 110mL/hour with (SD ± 25.85). The range for the intravenous fluids 
administered was minimum IVF rate was 50mL/hour with a maximum of 175mL/hour.  
For the 51 observation encounter medical records reviewed the mean IVF rate was 
110mL/hour with (SD ± 25.29). The range for the intravenous fluids administered was 
minimum IVF rate was 50mL/hour with a maximum of 175mL/hour, which was the 
similar findings for the inpatient encounters.  For the medical records reviewed 
regardless of hospital status based on weight the maintenance dose is 2-3 liters per 
day for IVFs administered, IVFs rates were determined less than adequate in 59% of 
the inpatients and 47% of the observation patients and are described in Table 7. 
Table 7.  
Intravenous Fluid Rates  
Adequate Rate (Inpatient)    n          %       Adequate Rate (Observation)     n         %__       
Yes                                       46       39.3         Yes                                       21      41.2 
Too low                                 69       59.0         Too low                                24       47.1 
Too much                               0            0         Too much                               2        3.9    
Not administered                    2         1.7         Not administered                    4        7.8__ 
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     One of the treatment recommendations from the NHLBI, 2002 is the appropriate 
assessment and intervention of potassium repletion based on blood chemistry 
analyses. Of the 168 medical records reviewed which included 117 inpatient and 51 
observation encounters there was a very small percentage of encounters with recorded 
potassium repletion, which was appropriate based on serum chemistry results for each 
encounter within the first 24 hours of either the inpatient admission or observation 
status encounter. Of the 117-inpatient status encounters there were 105 (89.7%) 
inpatient encounters without potassium repletion being administered, while 9 (7.7%) did 
receive intravenous potassium repletion; 3 (2.6%) received 20 milliequivalents (mEq) of 
potassium and 6 received 40 mEq of potassium. There were 3 (2.6%) inpatient 
encounters with no documented data. Of the 51 observation status encounters 50 
(98%) had no documentation of potassium repletion with 1 (2%) having documentation 
of potassium repletion of 40 mEq based on laboratory chemistries.  
          Opioids are one of the main clinical practice cores of pain management in sickle 
cell disease. The recommendation from the NHLBI (2002) is that “pain management 
should be aggressive to relieve pain and achieve maximum function expediently.” 
Severe pain in SCD should be considered a medical emergency which therefore needs 
prompt and timely treatment: 
1. Begin hydration: the initial fluid should be 5% dextrose + half-normal saline with 
20 mEq KCL/L adjusted for serum chemistries.  
2. Assess the cause of pain and any complications. Determine medications or 
treatments taken at home, including usual drugs and dosages, and any potential 
side effects during acute pain. Then use the opioid dosage which provided 
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adequate analgesia at a previous time engaged in care (for the patients known to 
a practice with a previous treatment history).  
3. Avoid intramuscular injections. However, if unable to obtain intravenous access, 
the subcutaneous route for administration of opioids is effective and acceptable.  
4. Frequent assessments of pain intensity, relief, mood, and sedation level are 
required every 15 to 30 minutes after each dose of medication. 
5. Titration to relief is an important aspect of care, regarding the nature of recurrent 
pain episodes and for consistent management of acute pain episodes. Titration 
can be achieved with aggressive dosing and with frequent or close monitoring; 
bolus dosing should be set at timed intervals after a loading dose, or “by the 
clock” (BTC) dosing, such as morphine 4 mg every 2 hours.  
6. Disposition at the conclusion of treatment must also be considered, whether an 
individual is being discharged from the ED or from the inpatient setting.  
Individuals need prescriptions for equivalent doses of pain medication to maintain 
pain relief. However, after aggressive treatment is given and pain relief is not 
achieved, inpatient admission should be considered (NHLBI, 2002). 
Of the 117 medical records reviewed with inpatient status the standard of care for most 
commonly used opioid was hydromorphone 99 (84.6%) with morphine 17 (14.5%) and 
1 (0.9%) undocumented data. Of note, there was one (0.9%) record with oral 
administered opioid within the first 24 hours of admission, the documented pain score 
was “7” and labeled “unacceptable”. The medication documented for treatment was 
Morphine 30mg immediate release tablets with two, one tablet doses given during the 
first 24 hours. This was supplemented with “as necessary” (prn) Ultram for 2 doses 
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during this same 24-hour period. The dosing for both medications was every four 
hours. There were 2(1.8%) inpatient status encounters with no opioid pain medication 
being documented for the first 24 hours of the inpatient admission. The first medical 
record reviewed in which no opioid was given the patient reported pain score was 
documented as “9/10” and labeled “unacceptable” for the patient. The second medical 
record reviewed the patient reported pain score was “6/10” and labeled as “acceptable” 
with the pain level rising to “10/10” and being changed to “unacceptable” with no opioid 
medication being administered in the first 24 hours of the inpatient admission. There 
was no documented explanation for the withholding of opioid pain medication in either 
medical record. Both medical records had documented the use of the non-steroidal 
anti-inflammatory (NSAID) drug ketorolac at least once for each in the first 2 hours. 
There were 51 medical records reviewed with observation status. The standard of care 
for the most commonly used opiate was hydromorphone 45 (88.2%). Table 8 contains 
frequencies for cases with hydromorphone and morphine administration.  
Table 8. 
Opioid Medications 
NHLBI Guidelines            (Inpatient) n=117     %            (Outpatient) n=51       %               
             Morphine                     17                14.5                   6                       11.8 
             Hydromorphone          99                84.6                  45                      88.2 
             None                             1                  0.9                   0                           0 
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     The NHLBI 2002 guideline highly recommends opioid medication administration 
with the use of patient controlled analgesia (PCA). For the medical records reviewed 
for this post hoc quality improvement project PCA was the usual route of IV 
administration. It was noted for the 117 inpatient status records reviewed there were 8 
(6.8%) encounters where “bolus dosing” was used with the timing parameters of “every 
1-4 hours’ prn”.  It was also noted for the 51-observation status medical records 
reviewed that there were 6 (11.8%) encounters where “bolus dosing” was used with the 
timing parameters of “every 1-4 hours’ prn”. There was no identifiable documentation 
for the reasons these individuals were not administered medication using PCA during 
these hospital encounters. 
     The utilization of hydromorphone for the management of vaso-occlusive crisis pain 
episodes was greater in this post hoc medical record review than the use of morphine. 
To further understand the impact of these medications the contexts of the dosages the 
morphine equivalents for hydromorphone as compared to morphine were calculated to 
facilitate an accurate comparison of opioid utilized and administered. This calculation 
was based of the recommended dosing of the NHLBI (2002).   One important 
difference between morphine and hydromorphone is the potency of the opioids. 
Dilaudid a synthetic derivative of morphine has been estimated to be as little as one to 
four times more potent and maximally one to ten times more potent than morphine 
(Felden et al 2011; Myers-Glower 2013 & Gulur et al 2015). This facility’s pharmacy 
parameters for the potency of Dilaudid have been utilized on a one to six ratio (Facility 
Pharmacy, 2010). Of the 117 inpatient medical records reviewed during the first 24 
hours of the inpatient admission the opioid mean equianalgesic dose administered for 
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hydromorphone was 2.68mg (SD ± 3.31), the mean equianalgesic dose administered 
for morphine was 13.04mg with (SD ± 11.84). Of the 51 observation, medical records 
reviewed the mean equianalgesic dose administered for hydromorphone was 2.32mg 
(SD ± 1.81), the equianalgesic dose for administered for morphine was 13.35mg (SD ± 
12.13). The range of opioid administered for inpatient encounters during the first 24 
hours of the admission was a minimum of 0mg to a maximum 53.33mg of morphine per 
dose. The mean sum for opioid equivalent doses (both morphine and hydromorphone) 
administered in the first 24 hours for the inpatient encounters was 1513.26mg.  The 
range of opioid equivalent doses administered for the observation encounters was a 
minimum of 0.25mg to a maximum 66.66mg as morphine equianalgesic doses. The 
mean sum for opioid equivalent doses administered in the first 24 hours for the 
observation encounters was 681.17mg.  
       One of the methods utilized for the administration of opioids reviewed was patient 
controlled analgesia (PCA). This study evaluated the number of doses that were 
attempted hourly and the number of doses that were actually given hourly during the 
first 24 hours of inpatient and the first 24 hours of observation status care for adults 
admitted with a sickle cell pain episode to current guidelines of the NHLBI. There were 
105 inpatient encounters reviewed with 12 encounters with no documented data. For 
PCA injects attempted hourly the range was 0 to 44 attempts M=7.19 (SD ± 6.26). For 
this same group the number of PCA injects delivered hourly range was 0 to 15 M=5.26 
(SD ± 3.55). There were 43 observation encounters reviewed with 8 encounters with no 
documented data. For PCA injects attempted hourly the range was 0 to 26 attempts 
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M=6.44 (SD ± 5.98). For PCA injects delivered hourly for observation encounters the 
range was 0 to 14 delivered hourly M= 4.39 (SD ± 3.37).   
      Rapid titration to pain relief is one of the recommendations of the NHLBI for the 
treatment of the sickle cell individual experiencing vaso-occlusive pain episode to make 
the pain more tolerable and manageable while being hospitalized. It was noted that at 
the facility all individuals being treated for VOC of sickle cell disease with continuous 
dosing of an opioid for pain management or basal rate dosing, per hospital policy, 
allowed for hourly increasing or up titration for pain (Facility policy, 2000). This titration 
allows the nursing staff to assess and modestly increase opioid medications based on 
patient reporting of pain and symptoms. This policy was adopted in congruence with 
the NHLBI 2002 treatment recommendations. However, of the 117 inpatient encounters 
reviewed, seven inpatient encounters were missing data and 103 (88%) encounters 
had no increase or up titration during the first 24 hours of admission. Only 7(6%) of the 
inpatient encounters had titration changes noted with only 2 (1.71%) of those changes 
being increases in opioid.    For the 51 observation encounters reviewed with three 
observation encounters with missing data 46 (90.2%) encounters had no increase or 
up titration during the first 24 hours of admission. Only 2 (3.9%) had up titration 
changes noted during the first 24 hours of admission.  
     The use of non-steroidal inflammatory medications (NSAIDS) is strongly 
recommended by the NHLBI during the first 24 hours of inpatient and the first 24 hours 
of observation status care for adults admitted with a sickle cell pain episode. Of the 117 
inpatient medical records reviewed the use of non-steroidal anti-inflammatory 
medications (NSAIDS) were used primarily for an indication of pain as noted for 72 
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(61.5%) inpatient encounters with 45 (38.5%) inpatient encounters with no documented 
data. The number of NSAIDS doses given ranged from 1 dose to 4 doses, M = 2.07 
(SD ± 0.86). For the inpatient medical records reviewed the most commonly used 
NSAID was ketorolac and route of administration are described in Table 9. Of the 51 
observation, medical records reviewed the use of non-steroidal anti-inflammatory 
medications (NSAIDS) were used primarily for an indication of pain as noted for 23 
(45.1%) medical records with 28 (54.9%) medical records with no documented NSAID 
administration. The number of NSAIDS doses given ranged from 1 to 4 doses on 
average with M = 1.87 (SD ± 1.01). For the observation encounters the most commonly 
used NSAID was ketorolac and route of administration is described in Table 9.  
 
 
 
 
 
 
 
 
 
 
63 
 
Table 9.  
Non-Steroidal Anti-inflammatory Drugs 
NSAIDS                      Dosage              Interval               (Inpt) n       %       (Outpt) n         %             
             Ketorolac       15mg-30mg        Every 6 hours        72          100         24             100    
             Ibuprofen       400mg-800mg    Every 4-6 hours       0              0          0                  0 
             Naprosyn       500mg                Every 12 hours        0              0          0                  0 
Route                                    (Inpatient) n          %            Outpt)n       %______        ______  
             IV                                        67           93.1                        22            95.7 
             Oral                                      5             6.9                          1              4.3 
             No documented data          45               0                         28                0 
Doses Administered         (Inpt)   n             %              (Outpt) n                  %_____________ 
             1                                21                  29.2                    11                    47.8  
             2                                31                  43.1                     6                     26.1 
             3                                16                  22.2                     4                     17.4 
             4                                 4                     5.5                     2                      8.7 
   No documented data           45                      0 __________28___               _0__________  
      
     The use of adjuvants is also strongly recommended by the NHLBI during the first 24 
hours of inpatient and the first 24 hours of observation status care for adults admitted 
with a sickle cell pain episode.  Of the 117 inpatient medical records reviewed, 
adjuvants were used to help manage symptoms related to pain management such as 
opioid induced pruritus and nausea. The indications are described in Table 10 as noted 
for 76 medical records reviewed and 41 records with no documented data.  The 
number of adjuvant doses given ranged from one to nine doses, M = 1.80 (SD ± 2.95). 
Of the 51 observation, medical records reviewed, 23 had no documented data. Their 
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indications are described in Tables 10 and 11 respectively. The range of adjuvant 
doses given was from one to ten doses on average with M=1.93 (SD ± 3.34). Adjuvant 
administration is described in Table 10 (Inpatient encounters) and Table 11 
(Observation encounters).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
Table 10.  
Inpatient Adjuvants  
Adjuvants              Dosage          Interval                n    percentage      Indication    n       (%)__ 
       Benadryl      25mg-50mg       4-6 hours           45        59.2          Pruritus        44     57.9 
       Atarax          25mg                 4-6 hours            1          1.3           Pruritus         1       1.3 
       Zofran          4mg-8mg           4-6 hours           16        21.1          Nausea        16    21.1 
       Baclofen      10mg                  8 hours               2          2.6            Spasms        2      2.6 
       Lyrica           50mg-600mg     12 hours             4          5.3            Pain              4      5.1 
       Neurontin     100mg-900mg   8-12 hours          3          3.9            Pain              3      4.1 
      Ativan            0.25mg-1mg      6-12 hours          5          6.6             Anxiety        6     7.9 
No documented data                                               41                                               66   ____   
Route                                                    n                                          Percentage ___________ 
      IV                                                    19                                            24.7 
      Oral                                                 58                                           75.3 
      No documented data                      40                                        _________________ 
Number of Doses Administered              n                                       Percentage__________ 
      1                                                           29                                            39.2 
      2                                                           21                                            28.2 
      3                                                            9                                             12.2 
      4                                                            7                                               9.5 
      5                                                            3                                               4.1 
      6                                                            4                                               5.4 
      7                                                            1                                               1.4 
     No documented doses                          43                                                   ______________  
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Table 11.  
Observation Adjuvants 
 
Adjuvants            Dosage              Interval                  n       (%)           Indication      n       (%)_  
      Benadryl      25mg-50mg        4-6 hours              17      60.7             Pruritus       17     60.7 
      Atarax          25mg                  4-6 hours               1        3.6              Pruritus         0          0 
      Zofran          4mg-8mg            4-6 hours               5      17.9             Nausea         5      17.9 
      Baclofen      10mg                   8 hours                  0          0              Spasms         0         0 
      Lyrica           50mg-600mg      12 hours                1        3.6             Pain              1       3.5 
      Neurontin     100mg-900mg     8-12 hours            1        3.6             Pain              1       3.5 
      Ativan           0.25mg-1mg        6-12 hours            3      10.6            Anxiety          4      14.4 
      No documented doses                                        23                                             23________                      
Route                                               n                                     Percentage _________________ 
      IV                                                8                                           28.6 
      Oral                                            20                                         71.4 
      No documented data                 23                                        _        ____________________ 
Number of Doses Administered              n                                        Percentage__________ 
      1                                                            10                                            35.7 
      2                                                            13                                            46.4 
      3                                                             3                                            10.7 
      4                                                             0                                                 0 
      5                                                             1                                              3.6 
      6                                                             0                                                0 
      7                                                             1                                              3.6 
      No documented doses                           43                                                  ______________  
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Summary of chapter    
 The NHLBI guidelines comparison to determine clinical patterns during the first 24 
hours of the inpatient admission clearly determined clinical practice pattern deficits in 
these dashboard measures: patient assessments, utilization of intravenous fluids, 
oxygen administration, and choice of pain medications including opioids, NSAIDS, and 
other adjuvants. Deficits were found for IV hydration and the selection of the 
recommended fluid, the titration of opioid medications to pain relief and inclusion of 
patient desired pain goals for the treatment of vaso-occlusive pain treatment during the 
first 24 hours of hospitalization regardless of inpatient or observation status.      
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 Chapter Five 
Discussion 
Oxygenation, Pain Intensity Scores, and Patient Pain Goals 
     The results of this post hoc medical review indicated that the health center nursing 
providers had a high rate of adherence with taking and recording vital signs for 
individual patients.  Of the 168 encounters reviewed, 90% of the patients had vital 
signs done every four hours which is a reasonable expectation for general care 
(NHLBI, 2002). The results from this post-hoc medical record reviewed were divided 
into two categories. The first category was a representation of the inpatient status for 
medical records with 117 encounters and the second category was a representation of 
the observation status with 51 encounters.   
     For this project study period the recording of oxygen saturation rates were very 
consistent for both the inpatient and observation status encounters. With the average 
oxygenation status maintained above 90% as recommended by the NHLBI 2002 
guidelines for treatment. It was unclear if oxygen was used because of low 
oxygenations rates or if oxygen was placed as comfort for those individuals that 
consider oxygen as “necessary” to aid in the alleviation of pain. The facility 
implemented a policy in January 2010 “sickle patients that need treatment with 
continuous dosing of an opioid and or basal rate are required to be maintained on 
continuous capnography for oxygenation monitoring congruently with treatment.” 
Limited literature is available regarding the implementation of capnography therapy, 
specifically for the individual with sickle cell disease for continuous opioid 
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administration. The Anesthesia Department of the hospital determined this additional 
step was warranted as a safety mechanism to guard for over sedation, while traditional 
use of capnography in sickle cell patients has been utilized in other instances, such as 
the management of acute chest syndrome- a life threatening complication, or for a 
patient that is in the intensive care hospital setting. In this instance the use of the 
Dartmouth Microsystem could help to establish evidence based parameters for the 
implementation for continuous capnography in the setting of continuous opioid or basal 
rate administration (Dartmouth Clinical Microsystem, 2005). The Dartmouth 
Microsystem could help to determine the overall process for the use of capnography 
and help to clearly identify the purposes for said therapy by focusing on patient safety 
and the possible reduction of over sedation. The use of capnography with continuous 
opioid use for the management of vaso-occlusive crisis events of the hospitalized 
patient could become more widespread thus helping to alleviate provider fears 
regarding the administration of opioids and in some cases the high doses that are 
required for the non-naïve opiate individual. This could be evaluated by the incidence 
of the hospitalized sickle cell individual and the occurrence of over sedation events 
while utilizing capnography therapy, thus, helping to establish improved care, 
enhanced safety, and new evidence for creating clinical patterns of pain management.  
     One major limitation with the use of capnography for the measurement of 
oxygenation is the non-existence of any previous literature or data available specifically 
for sickle cell disease vaso-occlusive crisis pain management. The facilities’ health 
program is currently demonstrating in real time the benefit of this modality as a tool in 
the management of pain with continuous dosing patient controlled analgesia.   
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     According to the data from this project the assessment and evaluation of pain for 
the sickle cell disease adult hospitalized experiencing vaso-occlusive crisis pain the 
mean intensity of pain for the inpatient encounters reviewed was 7.48 (SD±1.89) out of 
10 and for observation encounters reviewed the mean pain intensity level was 7.92 
(SD±1.48) out of 10. Most of the available literature discusses pain either in the 
outpatient setting which includes home or the emergency department. There is limited 
research that addresses the pain of the hospitalized adult whether inpatient or 
observation status which is a significant limitation specifically regarding titration and 
pain improvement. The presence of pain was acknowledged and consistently recorded 
for both settings. The “failure” for pain management in this study is directly tied to the 
very rare instances of up titration to alleviate pain. The continuous dosing of pain 
medications as written by the hospital policy (2000) allows for modest increases based 
on pain intensity scores. For the medical records reviewed for inpatient management 
only 7 (6%) of the inpatients and 2 (3.9%) of the observation population had titration 
changes with only two of those changes being increased medications for improving 
pain relief.  
     The implementation of the Dartmouth Microsystem (2005) processes would be 
utilized to reinforce and educate the nursing providers to execute established practices 
and utilize processes that have been placed specifically to improve patient care, and 
clinical practice. The Microsystem could be utilized to change the process if needed but 
the evidence from the available data identified the process for opioid titration has not 
been utilized as intended and needs to be addressed. The education for all care 
providers regarding this policy could lead to improved overall pain intensity scores with 
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an increase of titration for treatment in a timely manner as recommended by the 
NHLBI, 2002 guidelines.          
     This information poses an opportunity for future studies to explore and implement 
clinical practices that incorporate pain management guidelines that assist the provider 
(physician or advanced practice providers) to alleviate pain with titration 
recommendations written into the orders, assist the nurses to titrate according to the 
orders based on the pain intensity levels, provide patient safety, reduce complications 
from prolonged pain events, and increase administration of pain relieving medications, 
which is ultimately more patient centered care and a higher quality of care.  The 
implementation of orders sets and sickle cell specific protocols for the management of 
sickle cell vaso-occlusive crises pain has been recommended to promote higher quality 
care and improve clinical practice patterns (Lottenberg & Hassell, 2005; Ballas, 2010; 
Frei-Jones, Field, & DeBaun, 2009).   
     Patient reported pain goals, a critical part of the pain management assessment for 
both the inpatient and observation encounters as identified in this study, had two 
notable components. The first finding indicated for 52.1% of inpatient encounters and 
60.8% of observation encounters no data were documented for patient pain goals. 
Patient desired pain goals should be required to guide patient specific treatment. Lack 
of patient pain goals can unintentionally create underutilization of needed opioids. This 
can also be considered dismissive of the patients’ pain perception, which further adds 
to the distrust between patients and providers (Ballas, 2010) which can lead to 
ineffective treatment and prolonged pain.  Successful strategies could be implemented 
with the guidance of the Dartmouth Microsystem as a framework with the incorporation 
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of this needed assessment information to guide clinical practice for improved and 
optimal pain management. The NHLBI 2002, recommendations for rapid titration and 
inclusion of previously successfully implemented treatment support the need for 
obtaining this information. According to Ballas, 2005, “the patient’s self-report (of pain) 
is the most important factor in the hierarchy of pain management.”  The lack of this 
crucial information can be akin to the rendering of suboptimal care and disbelief of the 
patient’s pain experience.  
     A second finding for the patient reported pain goals was that many patients 
recorded acceptable levels of pain less than their desired pain goals. This may require 
some education on the part of the individual patient to understand the differences 
between an acceptable level of pain and what a desired level of pain actually means. 
Of the 117 inpatient encounters reviewed for pain goals during the first 24 hours of the 
admission 56 (47%) records recorded patient reported pain goals as M=3.0 (SD ± 
2.19). Of the 51 observation status encounters reviewed for pain goals during the first 
24 hours of the admission 20 (37%) records with patient reported pain goals were 
M=2.5 (SD ± 2.37). With the facility moving towards the implementation of the 
electronic health record called Epic by the year 2018 improving this process of 
determining patient pain goals could be “created as part one of the critical elements for 
care during the Epic build and followed as part of the quality improvement dashboard 
for improving clinical practice patterns. This would enable the recording of patient 
reported goals “hardwired” as the one of the new standards for care. The creation of an 
electronic template which may include “soft stops”-answer this question to continue 
and/or “hard stops” you cannot move past this point without inputting information, can 
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directly improve the opportunity to meet patient expressed pain goals. This would 
improve overall pain management and clinical practice patterns based on the 
subjective needs of individuals being treated for vaso-occlusive pain while hospitalized 
as recommended by the NHLBI 2002 guidelines. This will also allow the clinical care 
team more concrete information to assist in the process of ordering and titrating opioids 
to give the patient optimal analgesia.  
Intravenous Fluids and Intravenous Rates 
     The recommended intravenous fluid to promote optimal hydration and reduce the 
sickling viscosity of blood per the NHLBI 2002 guidelines is five percent dextrose and 
half-normal saline. These data present an opportunity to educate care providers 
regarding the utilization of hypotonic solutions such as five percent dextrose and half-
normal saline is useful because free water enters the hypertonic red blood cells, 
leading to a decreased hemoglobin concentration (MCHC) and reduced red blood cell 
sickling (Gavrillis & Rothenberg, 1973 & Bunn, 1997). Intravenous fluids should be 
infused to correct deficits and promote euvolemic states with adequate, fluid, and rates.  
     The recommended intravenous fluids rates per the NHLBI 2002 guidelines should 
not exceed “1.5 times maintenance (including volume for drug infusions).” For this 
study the inpatient encounters IVF rate 69 (59.0 %) were less than the recommended 
1.5 times the maintenance rate for IVF, none were determined to exceed the 1.5 
maintenance rate with 2 encounters of no documented data. For the observation 
encounters 24 (47.1%) were less than the recommended 1.5 times the maintenance 
rate for IVF, 2 (3.9%) was determined to exceed the 1.5 maintenance rate and 4 (7.8%) 
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encounters of no documented data. The NHLBI 2002 stresses the importance of 
adequate hydration to prevent further dehydration and promote euvolemic states in 
individuals experiencing vaso-occlusive pain crisis. Hydration status for individuals in 
crises is an important aspect of care the affects the pathophysiologic of sickling and 
dependent on clinical practice to promote hemostasis by utilizing IVF as part of the 
current clinical practices of the hospitalized adult (Ballas, 2010 & Yale et al. 2000). The 
recommended maintenance dose is 2-3 liters per day (Odesina 2001;SCIC 2005;Moritz 
& Ayus 2015; Okomo & Meremiku 2015). 
      While discussing intravenous hydration potassium repletion is also recommended 
by the NHLBI 2002 guidelines. There were a very small percentage of encounters with 
recorded potassium repletion within the first 24 hours of either the inpatient admission 
or observation status encounter. Of the 117 inpatient status encounters 105 (89.7%) 
had no documentation of potassium repletion with 3 (2.6%) having no documented 
data. Of the 51 observation status encounters 50 (98%) had no documentation of 
potassium repletion with 1 (2%) having documentation of potassium repletion based on 
laboratory chemistries. Little information regarding importance of potassium repletion 
was noted in the literature although it was also discussed in the 1999, American Pain 
Society guidelines for sickle cell pain management. Hypokalemia is a clinical 
manifestation that may accompany sickle cell vaso-occlusive crisis as either an acute 
kidney injury or cardiac dysrhythmia and should be carefully evaluated for everyone 
during a vaso-occlusive crisis pain event (Jaitly et al. 2008; Epstein, 2008). This is a 
limitation for this study and can be addressed in future studies.  
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     The Dartmouth Microsystem could be utilized to educate and monitor clinical 
practice changes to ensure implementation of the recommended intravenous fluids and 
the proper intravenous fluid rates are administer to optimize adequate hydration when 
the adult is not able to ingest sufficient fluids. The incorporation of the “4-2-1” rule for 
IVF could assist in determining the correct rates for administration of fluids based on an 
individual’s weight, which has been obtained upon admission, this can further be 
established with the creation of sickle cell specific protocols and order sets (Ballas, 
2010; Lottenberg & Hassell, 2005; Yale et al, 2000). 
Opioid Utilization 
     Opioids are one of the main clinical practice cores of pain management in sickle cell 
disease. The NHLBI, 2002 guideline recommendations can help direct treatment and 
help to improve the overall success of clinical practice in managing acute pain.  
The guideline recommendations (excerpt): 
 Assess the cause of pain and any complications. Determine medications or 
treatments taken at home, including usual drugs and dosages, and any potential 
side effects during acute pain. Then use the opioid dosage which provided 
adequate analgesia at a previous time engaged in care (for the patient which is 
known to a practice with a previous history of treatment). Avoid intramuscular 
injections. However, if unable to obtain intravenous access, the subcutaneous 
route for administration of opioids is effective and acceptable. Frequent 
assessments of pain intensity, relief, mood, and sedation level are required every 
15 to 30 minutes after each dose of medication. Titration to relief is an important 
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aspect of care, regarding the nature of recurrent pain episodes and for consistent 
management of acute pain episodes. Titration can be achieved with aggressive 
dosing and with frequent or close monitoring; bolus dosing should be set at timed 
intervals after a loading dose, or “by the clock” (BTC-by the clock) dosing, such 
as morphine 4 mg every 2 hours (NHLBI, 2002). 
        For this project, the most commonly utilized opioid for the inpatient encounters 
was hydromorphone 99 (84.6%), with morphine 17 (14.5%) for 117 inpatient status 
encounters. For the observation status encounters the opioids were utilized as follows 
hydromorphone 45 (88.2%) with morphine 6 (11.8%), for 51 observation encounters. 
Most encounters of the hospitalized adult for the treatment of vaso-occlusive crisis pain 
received some form of opioid to treat acute pain as recommended. There was however 
one (0.9%) where the opioid was administered orally. There was no documentation 
why the route was not intravenous. There also were two inpatient encounters where no 
opioid was administered in the first 24 hours and no documentation was available to 
support this practice for the two encounters, which did not follow the treatment 
recommendations for the NHLBI guidelines that opioid be given intravenous (Ballas, 
2010; Lottenberg & Hassell 2005; Frei-Jones et al, 2009).  
      The under medicating of individuals that present for vaso-occlusive crisis pain with 
the use of opioids can be directly related to provider bias and mistrust (Ballas, 2010 & 
Frei-Jones et al, 2009) this issue is not unique to the hospital but to the sickle cell 
community in general. This systemic problem needs to be addressed more succinctly 
across the many avenues individuals with sickle cell disease may reach out to for 
assistance in the management of VOC.  The aid the sickle patient would require is to 
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receive proper doses of medication, rapid treatment, rapid assessment, with titration of 
opioids to adequately address pain (NHLBI, 2002). The Dartmouth Microsystem (2005) 
can help with improving systems that can create evidenced based practices initiated 
from medical record information, previous successful treatments, hematological input, 
and help to eliminate provider mistrust (Dartmouth Microsystem 2005; Ballas 2010; & 
Frei-Jones, Field, & DeBaun, 2009). This provider bias and mistrust does not exist in 
pediatric sickle cell care and management which allows for comprehensive care, 
trusting provider and patient relationships and interactions, which translates to high 
quality sickle cell care (Ballas, 2010; Frei-Jones et al, 2009), which improves rapid 
treatment and provides for improved opioid management during a sickle cell vaso-
occlusive pain event.   
     This project also reviewed equianalgesic dosing for opioids administered during 
pain treatment of the hospitalized adult during the first 24 hours, this dosing was based 
on calculations for treatment as recommended by the NHLBI 2002 guidelines noting 
hydromorphone’s potency is 6 times greater than morphine (Felden et al 2011; Myers-
Glower 2013 & Gulur et al 2015; Facility Pharmacy, 2010). For the inpatient encounters 
for hydromorphone the M = 2.68mg (SD ± 3.31), for morphine the M = 13.04mg (SD ± 
11.84). For the observation encounters for hydromorphone the M = 2.32mg (SD ± 
1.81), for morphine the M = 13.35mg (SD ± 12.13). Generally, opioids were 
administered by using the recommended vehicle the use of PCA-patient controlled 
analgesia over bolus dosing or oral administration. The opioids administered were 
usually under-dosed for the management of patient pain as evidenced by documented 
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self-reported high level pain scores and continued reports of unacceptable levels of 
pain with opioid administration.   
     This study also reviewed data which observed how the PCA was utilized during the 
first 24 hours of the adult patient admission. For 105 (89.7%) of the inpatient 
encounters with 12 (10.3%) undocumented encounters data, the number of PCA 
injects attempted hourly M = 7.19 (SD ± 6.26) with a range of 0 to 44 attempted injects 
per hour. The number of PCA injects delivered for this same group was M =5.26 (SD ± 
3.55) with a range of 0 to 15 injects delivered hourly. For 43 (84.3%) of the observation 
encounters with 8 (15.7%) undocumented encountered data, the number of PCA 
injects attempted hourly M = 6.44 (SD ± 5.98) with a range of 0 to 26 attempted injects 
per hour. The number of PCA injects delivered for this same group was M = 4.39 (SD ± 
3.37). Solomon, 2010 suggests that opioid administration should be dependent on 
previous analgesic dosing and consider weight based dosing as recommended by the 
NHLBI 2002. Several studies agree the baseline for treatment with opioids should 
begin with the last previous efficacious dose if the individual in known to a practice of 
facility (Ballas, 2009; Solomon, 2010, NHLBI 2002).  Given the range and number of 
doses attempted for both populations the recommendation of the NHLBI to titrate to 
relief needs to be incorporated into any treatment regimen to improve the alleviation of 
pain and the efficacy of opioid treatments. This is further evidence that the doses for 
opioid given were generally seen to be less than required to provide analgesia or 
adequate pain relief.    
     The increasing or up titration of opioid treatments was rarely observed in the data 
collection of this post hoc medical record review. The hospital has included in the order 
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set for PCA dosing the parameters for modestly increasing the opioid dose for an 
individual in vaso-occlusive crisis pain hourly based on the patient report of pain and 
symptoms. For the inpatient encounters 103 (88%) had no increase or change in 
titration noted with 7 (6%) with no documented data and 7 (6%) with titration changes 
but only 2 (1.7%) were increases in opioid to manage pain. For the observation 
encounters 46 (90.2%) had not increase or change in titration noted with 3 (5.8%) with 
no documented data and 2 (3.9%) had increases or up titration to manage pain.  
     One possible conclusion for nurses not implementing the ability to titrate 
opioid pain medications modestly as the policy is written are the nurses concerns for 
over sedation, respiratory depression, and the inability to properly assess patients in a 
hectic environment of inpatient and observation hospital care along with provider bias 
regarding patients reporting of pain (Bernhofer, 2011). The ability to eliminate personal 
bias and judgments while providing care will allow optimal clinical practice, improved 
overall pain management, and increase patient satisfaction with hospital pain 
management (Dupree et al, 2009; Bernhofer, 2011, Ballas, 2010, NHLBI 2002). These 
processes are not intended to discount nursing concerns for patient safety. Educating 
and removing the emotionality from the process of using opioid medications especially 
with the ability to modestly titrate the opioid pain medications will allow for the provision 
for safe, appropriate, and humane care while providing adequate analgesia (Bernhofer, 
2011 & Dupree et al, 2009). The nurse can and should practice with the autonomy the 
hospital titration policy allows for to address adequate analgesia needs, and feel 
comfortable with the added dimensions that will be included in the electronic medical 
record as reminders of care that add to clinical practice and safety. The recruitment of 
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more providers trained to manage sickle cell disease could be very impactful in the adult 
population which would aid to decrease provider bias.  
     The use of the Dartmouth Microsystem (2005) should guide the pain management 
quality improvement processes and measure the implementation and effectiveness of 
the system changes. The NHLBI 2002 and the hospital 2000 treatment protocol is 
already in place. The providers should be educated to use the tools in place to titrate 
appropriately to alleviate pain. The facility policy can be reintroduced to the care 
providers to optimize the nurses’ role to increase the medications based on the 
assessment of the patient and within the ordered parameters for the individual on PCA 
continuous dosing. The clinical practice patterns can be reevaluated in set time frames 
to ensure the clinical processes positively impact the improvement of pain and the 
overall patient reported pain scores and acceptable levels of pain. This will allow the 
implementation of the recommended NHLBI 2002 as utilized by the facility to place into 
practice the specific clinical practices by use of the EPIC EHR system to expand the 
improvement of pain management during the first 24 hours of the inpatient 
hospitalization. The inclusion or possible revision of protocols specific for sickle cell 
disease management can again improve the speed of titration and quality of pain 
management clinical practice patterns. This can be implemented with the introduction 
of EPIC electronic health record (EHR) system in 2018, by creating sickle cell specific 
templates that directly address opioid administration and the frequency of monitoring 
during treatment. The nursing assessments created should specifically entail nursing 
concerns with sedation levels, respiratory status, alertness, and for the patient i.e. pain 
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goals, acceptable level of pain, location of pain, and patient satisfaction with care 
(Dartmouth Microsystem, 2005 & Bernhofer, 2011).  
NSAID and Adjuvant Utilization 
     The management of pain as recommended by the NHLBI 2002 should include 
NSAID and adjuvants to enhance opioid use if indicated. The use of NSAIDS in this 
study was primarily for the indication of pain. The most commonly used NSAID being 
ketorolac for both populations. The most frequently used route for administration was 
intravenously. The role of anti-inflammatory medications in the management of vaso-
occlusive crisis has two main functions-to help reduce the inflammation present 
because of the underlying sickle cell disease and to work synergistically with opioids to 
bring pain relief (APS, 1999 & NHLBI 2002).  
     According to the data from this study for the inpatient encounters the use of 
NSAIDS was utilized for more than half of those treated for pain while in the 
observation arm less than half were administered an NSAID. For both populations, 
there were thirty percent or more with no documented data for this parameter of NSAID 
use. Given the large percentage of undocumented data for the use on NSAIDS this has 
proved to be a limitation of the project. This project showed only modest use of 
NSAIDS and adjuvant therapies for the management of pain and the reduction of pain 
management induced symptoms. Either the providers are unaware of the clinical 
benefit the reduction of inflammation and the synergistic effect to enhance analgesia 
will provide or the clinical care providers need further education regarding the benefit of 
this class of medications for the use of sickle cell patients.  Given the clinical benefit for 
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this patient population it would be prudent to provide the basic education needed to 
allow this practice to become part of the standard of care. With the impending EHR this 
medication can be one of the staples for the order set or template for pain management 
of the sickle patient regardless of admission status.  
     The use of adjuvants was primarily for symptomatic complaints such as opioid 
induced pruritus or nausea.  For both populations, the adjuvants were primarily 
administered orally with more than fifty percent requiring medications to help combat 
opioid induced pruritus. The use of adjuvant also had a large number of undocumented 
data for both the inpatient and observation encounters. The most commonly prescribed 
adjuvants were Benadryl and Zofran, and were proven to be effective as administered 
orally. For the sickle cell patient that is receiving treatment for vaso-occlusive crisis 
episode pain the anticipation of pruritus and nausea could bring the added benefit of 
relief of unwanted symptoms while anticipating the relief of pain. The “hardwiring” of 
these medications into a sickle cell specific order set would impact clinical practice 
patterns positively and increase patient satisfaction with hospital care. This was not 
congruent with several recommendations for treatment in sickle cell specific guidelines 
(Ballas, 1995; NHLBI, 2002; Rees et al, 2001). Particularly the use of ketorolac has 
been shown to decrease the need for utilization of opioids and enhance vaso-occlusive 
crisis pain management for the sickle cell patient.  
Limitations 
     There were limitations to this quality improvement project. This project was limited 
to a small university health center with a relatively small patient sample size. The 
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design for a quality improvement project was a retrospective post hoc medical record 
review for a period of one full year January 1, 2014 thru December 31, 2014. The 
sample for medical review had multiple encounters for several medical records. During 
the data collection phase, it was noted several encounters had been admitted first as 
observation and then later converted to an inpatient admission. This was addressed by 
separating the different admission statuses and evaluating them separately. Patients 
that had inpatient care should have improved outcomes from patients being cared for 
23 hour, inpatient data would be more conservative regarding deficits.  However, the 
data for both patient populations had similar outcomes and deficits despite the 
intervention of 23 hours of ongoing treatment prior to admission. The instrument used 
for data collection was created specifically for this quality improvement project. The 
instrument was modified to incorporate more data and may need to the updated and 
generalized for replication for other area studies.   
     The age of the data could be considered a limitation of this project. The data was 
abstracted for the year 2014.  Although several institutional changes were made since 
the data were collected inpatient care managed by the inpatient team has remained 
unchanged, and therefore unlikely to impact data relevance. The data was collected by 
the student investigator who was also an employee of the hospital. The potential for 
bias during data collection is counterbalanced by the investigator’s expertise with the 
system and institutional practices for sickle cell pain management.       
     It would be important for future studies to ascertain if oxygen is donned for comfort 
measures or if truly deemed hypoxic. This determination may prove impactful in other 
treatment areas and needs to be fully assessed to ensure if underlying pathology is 
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present it can be fully and appropriately treated. The use of capnography with 
continuous dosing of intravenous opioids could be a lifesaving measure and needs 
further evaluation and documentation. The limitation of previously available literature 
for treatment comparisons creates a unique opportunity to promote this pilot project 
information to create the opportunity for change and improvement for other treatment 
facilities by adjusting care parameters for opioid dosing thus increasing the ability for 
opioid continuous dosing improving pain treatment overall for sickle cell patients. 
     Pain management for the hospitalized adult in sickle cell vaso-occlusive crisis pain 
is a limitation and may not be able to generalize to other facilities. However, the 
different aspects of pain management can be evaluated in other facilities and include: 
the pain measurement tools, the assessment documentation, and evaluation for the 
frequency of titration to analgesia-all important aspects of pain management that can 
be evaluated for improvement. Paramount to this process and a limitation is the 
inconsistency for determining patient desired pain goals. This information needed to 
determine analgesia parameters and can be evaluated in other settings to guide the 
pain protocols and help to create sickle cell specific algorithms to help patients reach 
improved pain states. This should also include ensuring adequate doses of opioids are 
administered and titrated for unacceptable levels of pain. Although the hospital policy 
allowed for modest titration of the opioids based on the patients reported levels of pain 
it was unclear why this was not carried out. The parameters were clearly listed as part 
of the medication administration record. Perhaps reeducation may be required to 
implement options that are available to help improve pain.  Lastly, the modest use of 
NSAIDS and adjuvants could be significantly improved once the reasoning is 
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determined for the underutilization. This could easily be replicated at other facilities to 
ensure optimization of available therapies utilized as therapeutically as indicated.   
Implication for Future Studies 
     This quality improvement project can be replicated in different facilities across the 
country to determine their clinical practice patterns for the management of sickle cell 
disease within multiple settings. The evaluation of key elements can help to determine 
what areas of practice need improvement and what is being done well that should be 
sustained. Sickle cell patients reside all over this country and this information is 
applicable to all who manage individuals living with this chronic debilitating disease. 
This type of quality improvement project can help to bridge the distress that some 
providers may have in regard to the self-report of patient pain without the benefit of 
objective findings for acute pain management.  
     One of the issues that may be of interest is the use of oxygen. The use of oxygen 
for many individuals experiencing sickle pain has associated comfort with this practice 
for pediatric care. This can be addressed by determining true hypoxemia and the 
clinical need for oxygen versus placating a request because of previous use. This 
determination could be valuable in future studies regarding clinical practice patterns for 
oxygenation. The proper intravenous fluid utilized for hydration is another area for 
clinical practice that can be assessed and evaluated. Unless an individual being treated 
is deemed to be hypovolemic then the recommendations by the NHLBI 2002 for 
rehydration should be followed unless contraindicated. Rehydration should include the 
parameters of fluid rates- “not to exceed 1.5 times maintenance including volume for 
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drug infusions”, along with closely monitoring serum chemistries for hypokalemia and 
the need for potassium repletion as needed, this was not an issue as indicted with the 
data collected.  
     Opioid dosing should be closely evaluated and titrated appropriately to meet the 
needs of the individual. This should include reviewing patient passports if available, 
previous successful opioid treatments, and reliable patient reporting where applicable. 
Under dosing of pain medications should be avoided to prevent untoward 
complications from prolonged pain events. The use of PCAs as recommended by the 
NHLBI should be utilized where available.  This should also include the frequent 
assessment of the patients reported pain levels, desired pain goals measurements, 
and acceptable levels of pain. This should be discussed with the patient at frequent 
intervals to ensure pain is improving and becoming tolerable for the patient. This 
should incorporate titrating medications to meet the patient’s pain needs versus 
keeping an individual on the same dose for several days with little to no improvement 
which causes prolong pain, lengthens the hospital stay, decrease patient satisfaction, 
and disrupts family and home lives.  
     Lastly incorporating the use of NSAIDS and adjuvants routinely in specific sickle cell 
care can help reduce complications associated with opioid pain management i.e. opioid 
induced pruritus, constipation, and nausea. For some patients being treated with 
opioids, pruritus can be extremely severe and debilitating to the degree of causing 
lacerations from scratching with miscellaneous objects. This side effect should not be 
ignored and may not respond to Benadryl; effective treatments need to be researched 
and evaluated to decrease the severity of this issue. Treatment with Naloxone has 
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proven to be effective in some instances but replication of this practice is needed to 
verify the efficacy of this practice.  Nausea should also be treated proactively with the 
use of strong opioids to prevent further dehydration which can lead to worsening 
sickling. Oral administration of these medications is preferred however in the presence 
of active vomiting intravenous route is acceptable. Care providers should encourage 
adequate nutritional support when appropriate. Evaluating the use of these medications 
can help establish improved sickle cell specific treatment guidelines and protocols for 
sickle cell inpatient care with replication of use in multiple settings. 
Implication for Practice 
     The clinical practice patterns for this quality improvement project has documented 
several areas for quality improvement that will be addressed: hydration- the type of 
intravenous fluids administered, titration of opioids for pain relief, and the recording of 
patient desired pain goals.  Hydration-for this project it was noted the recommended 
IVF was underutilized five percent dextrose and half-normal saline for more than half of 
the fluids administered. The use of the correct fluid is crucial for restoring homeostasis 
and a euvolemic state for the individual experiencing vaso-occlusive crisis pain. 
Titration for the alleviation of pain – the most important aspect of care for the individual 
seeking care, rapid titration and the increase of opioid dosing is critical to pain 
management and needs to happen in a timely manner with the proper assessments for 
evaluation of treatment. As stated previously titration of opioids for improving pain the 
hospitalized sickle cell patient for vaso-occlusive pain is critical. For patients reporting 
high levels of pain in comparison to patient reported desired level for pain and or 
acceptable pain levels the practice should be to increase the doses and reassessment 
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until pain has improved. This can be done by giving specific parameters for increasing 
opioid dosing with nursing assessments and evaluations. Modest increase can be 0.5 
to 1mg. hourly to every two hours with frequent assessments especially in the patients 
that are taking chronic opioids at home. Patient desired pain goals will become the 
gauge for which pain management is administered and titrated.   
Clinical Dashboard 
     The creation of the clinical Dashboard will be completed by the Facilities’ Hospital IT 
Department at the direction of nursing administration and the medical director for the 
Adult Comprehensive Sickle Cell Program in anticipation of the electronic medical 
record program Epic 2018. The clinical Dashboard will focus on three outcomes of this 
quality improvement project which has been presented to the Nursing Administration. 
The three outcomes of focus: 
Hydration: intravenous hydration- to follow the NHLBI recommendation of dextrose five 
percent with half strength (0.45%) of normal saline, unless active vomiting is noted. 
Titration: quickly administering adequate doses of pain medication to help achieve 
maximal levels of comfort as quickly and safely as possible. 
Patient pain goals: the accurate recording of patient reported pain goals to assist with 
optimal pain relief as guidance for pain management.  
    A concerted effort on the part of providers will be required to create, implement and 
monitor the required changes to improve the overall quality of care administered to 
sickle cell adult patients. The current clinical practice patterns will be transformed to 
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manage patient needs correcting the identified treatment deficits during the first 24 
hours of inpatient and the first 24 hours of observation status care for adults admitted 
with a sickle cell pain episode to current guidelines of the NHLBI for emergency 
department care utilizing the Dartmouth Microsystem quality improvement initiatives for 
populating the clinical dashboard. 
     The clinical dashboard will be based on information extracted from the 
implementation of the electronic health record EPIC in 2018. The Epic program can be 
designed to include disease specific order sets that can guide clinical practice. In 
particular, the order sets for sickle cell disease management can include parameters 
for intravenous hydration which includes the type of fluid and rate. An example of 
disease specific sickle cell orders sets is displayed here as Exhibit A. 
Exhibit A. Sickle Cell Infusion Order Set Sample 
 
The order set can also include specific parameters for example the outpatient 
treatment of a vaso-occlusive crisis episode that would be administered in the day 
hospital a Sickle Cell Infusion as displayed here in Exhibit B. 
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Exhibit B. SCD Order Set Sample 
 
The creation of the Epic design has some unique features that can be capitalized upon 
for each different facility to cater (attend to the needs of) to unique patient populations. 
Thus, creating individualized care- creating higher quality clinical practice patterns 
within disease specific protocols. These order sets can include laboratory requests and 
orders for the administration of antibiotics if deemed necessary to meet an individual 
patient’s clinical needs, this is displayed here with Exhibits C, D, and E. 
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Exhibit C. SCD Order Set Sample A 
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Exhibit D. SCD Order Set Sample B 
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Exhibit. E SCD Order Set Sample C 
 
With the use of these types of orders sets guiding clinical practice, the monitoring of the 
clinical practices changes shall be simplified with collaborations between the nursing, 
medical and IT departments. This would be specifically designed and guided with the 
Dartmouth Microsystem (2005) with the implementation of the five “Ps.” 
     The actual clinical dashboard will be created by the healthcare team, patients, IT 
department, and ancillary stakeholders involved with care for individuals with sickle cell 
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disease. Cooperatively the clinical dashboard will be created inclusive of the different 
variables of the Epic electronic medical record. The clinical dashboard will focus on the 
care being monitored hydration, titration, and patient pain goals. This will aid with the 
goal of visually observing the achievement of benchmarks towards improving clinical 
practice and improving the quality of care. The clinical dashboard may look similar to 
the example displayed here with the appropriately label interventions see Exhibit F. 
95 
 
Exhibit F.  Clinical Dashboard Sample
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Exhibit G. Clinical Dashboard Sample A 
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Exhibit H. Clinical Dashboard Sample B 
 
      The goal for the creation of the clinical dashboard for the hospital will be to provide 
a clear picture of the care being provided using visualizations as seen in these 
examples.  A dashboard is utilized to convey relevant information to clinicians and 
leadership in a way that communicates quantitative data that is easily understood. This 
98 
 
aids in the ease of sharing information and correcting deficits. The dashboard also 
allows for tracking specific measures and clinicians to own where data needs are on 
track.  The dashboard can also allow in an organized manner information regarding 
financial, operational performance, along with clinical performance which can add to 
cost saving measures. The metrics to be reviewed: hydration, titration, and patient 
desired pain goals, to determine if clinical practices changes are being adhered, 
exchanged- as proficiency develops to improve other clinical practices, updated as 
benchmarks are met; monitoring all to ensure ongoing high quality improvements and 
overall care improvements. These are important parameters that should be addressed 
as part of the Epic build team for the sickle cell disease protocols.  
Implication for Policy 
     The hospital has implemented two key policies for the care of sickle cell patient. 
One of the first being the use of capnography for continuous dosing with opioids by the 
pharmacy department. This policy could have long reaching implications for policies in 
other facilities that may consider the use of continuous opioid dosing for sickle cell 
vaso-occlusive pain as a safety and prevention measure. Determining the impact of 
this policy in other locations and facilities could globally expand opioid use in pain 
treatment especially with the negative connotation associated with these medications in 
the media because of misuse and high profile deaths of superstars like Prince and 
Michael Jackson.   
     The second policy allows for modest titration of an administered opioid based on 
pain levels of the sickle cell patient being treated for vaso-occlusive crisis pain episode. 
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This policy if followed as ordered allows the nurse to incrementally increase the dose of 
opioid setting on the PCA to improve analgesia. This increase allows for slowly titrating 
pain medications with nursing assessments and documentation. This also allows the 
nurse to titrate down for the patient that has achieved analgesia and is ready to be 
tapered down on the opioids. These changes in care for patients can be impactful by 
eliminating wait time for orders and delays in treatment. These policies do not eliminate 
the need for provider involvement but focus the care on getting pain under control 
expeditiously. However, this policy has not improved outcomes yet. The 
implementation and use of these policies will impact positively the quality of care and 
improve the clinical practice patterns currently in place while improving patient 
satisfaction with inpatient and observation care. The policies can easily be adopted for 
use at other facilities and help provide higher quality care for the adult admitted with 
vaso-occlusive crisis pain. The inclusion of the nursing leadership for the hospital 
health will help push the initiative to provide high quality care, which will improve trust 
and satisfaction for both the patient and the provider.   
Implication for Education 
          The introduction of the Dartmouth Microsystem will create the opportunity to 
educate the care providers, especially the nursing staff regarding clinical practice 
patterns of focus-hydration, titration to pain relief, and patient desired pain goals.  The 
systematic approach will use the 5 P’s “purpose-, patients, professional, processes, 
and patterns. The education will clarify the global aims for the quality improvement 
project, for the staff (healthcare team) and other stakeholders-whom are patients, IT, 
social workers, care coordinators, pharmacy and administration , and be evaluated by 
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the creation of the dashboard with the implementation of the electronic medical record 
Epic in 2018.   
Conclusion 
     Sickle cell disease impacts healthcare utilization, families, and individuals living with 
the disease in a fashion unlike other chronic illnesses. This quality improvement project 
can have long lasting implications for improved care of the hospitalized adult, creating 
evidenced based disease specific protocols that can lead to improved pain 
management. This, in turn, can lead to faster recovery and departure from the hospital. 
Improving titration to analgesic effect, decreasing hyper-viscosity by administering the 
correct intravenous fluids at the appropriate rates, and providing adequate opioid 
management to address each individual desired pain goals will ultimately impact quality 
of life and function. Having a clinical dashboard to monitor and evaluate overall clinical 
care patterns allows for corrective action more expediently and applauds the 
continuance of meeting and exceeding clinical benchmarks visually. This project was 
undertaken to improve inpatient clinical practice patterns for the hospitalized adult 
during the first 24 hours of the inpatient admission.  With the results and the creation of 
the clinical dashboard, improvements will be achieved over time including the creation 
of improved clinical practice patterns and eventually improved outcomes for the adult 
with sickle cell disease.    
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Appendix A 
 SCARDS (Sickle Cell Audit Record Data Sheet) 
SICKLE CELL AUDIT RECORD DATA SHEET (SCARDS) 
Medical Record Unique ID#                                                             Date of Audit:
Gender:       □  F       □ M                                Age: 
Race:   
□Black or 
African American  
□Hispanic/Latino 
□White   
□Unknown                                               
Ethnicity: 
□Jamaican 
□Haitian 
□African 
□Caribbean Islander 
□Mexican 
□Puerto Rican 
□Columbian 
□Italian 
□Turkish 
□Greek 
□Non Hispanic/Latino 
 
Genotype:  
□HgSS 
□HgSC 
□HgSβ+ 
□HgSβ○ 
Marital Status: 
□Single 
□Married 
□Divorced 
□Widowed 
 
Primary Dx: Secondary Dx: 
Admit Date:                          Time: Discharge Date: 
Vital Signs: 
T:               P:              R:             B/P:                      POX:                 WT: 
T:               P:              R:             B/P:                      POX:                  
T:               P:              R:             B/P:                      POX:                 
T:               P:              R:             B/P:                      POX:                 
T:               P:              R:             B/P:                      POX:                 
T:               P:              R:             B/P:                      POX:                 
Oxygen:  □Yes    □No     Liters:   Apparatus:  □ NC    □ Mask   Nebs:  □Yes    □No 
Frequency of Assessments: 
Time:  Pain Intensity: Prompt Treatment: Pain Relief: 
    
    
    
    
    
    
    
    
    
    
    
Frequency of Reassessments: 
Timing Q15-30:  Timing after admin of 
meds:  
 
Pain intensity:   Relief: Mood:   Sedation level: 
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Intravenous Fluids: 
NS 0.9%                       
□Yes    □No                                  
Amount: Rate: D5%W                         
□Yes    □No 
Amount: Rate: 
NS 0.45%                     
□Yes    □No                                   
  D10%W                       
□Yes    □No 
  
NS 0.225%                   
□Yes    □No                                       
  D5NS                           
□Yes    □No 
  
Ringer’s Lactate           
□Yes    □No 
  D5 ½ NS                      
□Yes    □No 
  
D5 Ringer’s Lactate       
□Yes    □No 
  D5 1/3 NS                    
□Yes    □No 
  
Potassium Repletion            □Yes    □No Dosage: 
Opioid Administration 
Adults with ≤ 50K Body Weight: 
Opioid Dosage Frequency IV SQ PCA 
Basal-Bolus 
Morphine       
Hydromorphone       
Adults with ≥ 50K Body Weight: 
Opioid Dosage Frequency IV SQ PCA 
Basal-Bolus 
Morphine       
Hydromorphone        
Oxymorphone        
*Meperedine 
Not Recommended  
     
NSAIDS/Adjuvants 
Medication Dosage Route Frequency Effects Time 
Ketorolac      
Motrin      
Naprosyn      
Benadryl      
Atarax      
Zofran      
Muscle 
Relaxants 
     
Benzodiazepine      
Allergies  
Location During Admission 
Oncology 6 Med 4 ICU Cardiac 
Stepdown 
Med 5 OB 
      
      
      
Table 1. NHLBI SCD Vaso-Occlusive Management Recommendations 
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Table 1. NHLBI SCD Vaso-Occlusive Management Recommendations 
Assessment and Reassessments: for the individual’s pain episode 
Initial rapid assessment- 
of acute painful episode 
including pain intensity, 
prompt treatment and 
relief.  
Reassessments – 
frequent reassessments 
every 15-30 minutes after 
the administration of pain 
medications for pain 
intensity, relief, mood, and 
sedation level.  
Response to therapy – 
reported reduction in pain 
intensity of at least 50-
60% from the upper end 
of pain score. 
 
Intravenous hydration: 
Initial fluid should be 5% 
dextrose + half-normal 
saline.  
Add 20 mEq KCI/L 
adjusted for serum 
chemistries.  
Total fluids not to exceed 
1.5 times maintenance 
dose. 
Administration of Oxygen: 2 liters via nasal cannula for patients with pulse oximetry 
of 92-95% 
Administration of Opioids and Adjuvants: Short-acting opioid agonists 
For adults with ≤ 50 kg body weight: 
Morphine: 0.1-0.15 mg/kg every 2-4 
hours (parenteral); 0.30 mg/kg every 3-4 
hours (oral). 
Hydromorphone: 0.015-0.020 mg/kg 
every 3-4 hours (parenteral); 0.06-0.08 
mg/kg every 3-4 hours (oral).  
*Meperidine: not recommended 
For adults with ≥ 50 kg body weight: 
Morphine: 5-10 mg every 2-4 hours 
(parenteral);  
10-30 mg every 3-4 hours (oral). 
Hydromorphone: 1.5 mg every 3-4 hours 
(parenteral); 7.5 mg every 3-4 hours 
(oral).  
Oxymorphone: 1.0-1.5 mg every 6hours 
(parenteral) or 0.5 mg IV and cautiously 
titrate upward. *Meperidine: not 
recommended 
Other routes of administration: Subcutaneous (for the individual with poor or no 
venous access to prevent delays in treatment) and patient controlled analgesia 
(PCA). 
Non-steroidal anti-inflammatory drugs (NSAIDS): 
Ketorolac (parenteral) for inadequate analgesia after optimal titration or when the side 
effects of opioids are problematic (maximum use of 5 days/month).  
Note. NHLBI Guidelines 2002 
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 Table 2.   
Demographic Information (n=54)   
Demographics n Percentage 
Gender  
Male 
Female 
 
23 
31 
 
42.6% 
57.4% 
Race 
African American 
White 
Hispanics 
 
48 
1 
5 
 
88.9% 
1.9% 
9.3% 
Marital Status 
Single 
Married 
 
45 
5 
 
83.3% 
9.3% 
            Divorced                                    4            7.4% 
 
    Genotype              
 HgSS                                      38             70.4%  
 HgSC                                      10             18.5%          
 HgSB+                                      6   11.1%     
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Table 3.  
Pulse Oximetry Measurements (N = 168)                                                                                                                                           
Inpatient Oximetry (n=117)                              Observation Oximetry (n=51) 
Measurements          n         %                  Measurements            n         %____________    
90                               0          0                         90                         1         2.0% 
92                               2        1.7%                     92                         1         2.0% 
93                               6        5.2%                     93                         1         2.0% 
94                               8        6.9%                     94                         3         5.9% 
95                               9        7.8%                     95                         2         3.9% 
96                               9        7.8%                     96                         4         7.8% 
97                             14        12.1%                   97                         6       11.8% 
98                             19       16.2%                    98                         9       17.6% 
99                              22      19.0%                    99                       15       29.4% 
100                            27       23.3%                 100                         9       17.6% 
No documented data  1          .9%_____________________________________  
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Table 4.   
Pain Intensity Scores   
              Inpatient                                                                   Observation 
Pain Intensity Scores           n      Percentage    Pain Intensity Scores    n     Percentage 
                  0                          1           0.9                             0                   0              0.0 
                  1                          0           0.0                             1                   0              0.0 
        2                          0            0.0                            2                   0              0.0 
                  3                          1           0.9                             3                   0              0.0 
                  4                          5           4.3                             4                   0              0.0 
                  5                          9           7.8                             5                   4              8.0 
                  6                         20         17.2                            6                   6            12.0 
                  7                         17         14.7                            7                   6            12.0 
                  8                         26         22.3                            8                 16            32.0 
                  9                         17         14.7                            9                 10            20.0 
                10                         20         17.2                           10                  8            16.0 
   No documented scores      1                                                                  1_________              
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Table 5.  
Patient Pain Goals 
Inpatient (n=56)                                               Observation (n=20) _______________         
Patient Desired Pain Goal                           Patient Desired Pain Goal 
Pain Goal          n      Percentage_______ Pain Goal          n         Percentage_______ 
       0               15         26.8                               0                 8                 40.0 
       2                 2          3.6                                2                 2                 10.0 
       3               15         26.8                               3                 2                 10.0 
       4               11        19.6                                4                 5                 25.0 
       5                3           5.4                                5                 0                    0 
       6                8          14.3                               6                 2                 10.0 
       7                2           3.6                                7                 1                  5.0 
Note. Data was not documented for n = 61 inpatient and 31 observation patient stays.   
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Table 6.  
Intravenous Fluids   
IVFs (Inpatient)        n            %             IVFs (Observation)                    n_       %    ___   
D5 NS 0.45%             46         40.0                    D5 NS 0.45%                 21        44.7 
NS 0.9%                    19          16.5                    NS 0.9%                          7        14.9 
NS 0.45%                  50          43.5                    NS 0.45%                      19        40.4 
No documented data   2          ____________No documented data          4          ___           
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Table 7.  
Intravenous Fluid Rates  
Adequate Rate (Inpatient)    n          %       Adequate Rate (Observation)     n         %__       
Yes                                       46       39.3         Yes                                       21      41.2 
Too low                                 69        59.0        Too low                                24       47.1 
Too much                               0             0         Too much                              2        3.9    
Not administered                    2          1.7         Not administered                   4        7.8__ 
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Table 8. 
Opioid Medications 
NHLBI Guidelines            (Inpatient) n=117     %            (Outpatient) n=51       %               
             Morphine                     17                14.5                   6                       11.8 
             Hydromorphone          99                84.6                  45                      88.2 
             None                             1                  0.9                   0                           0 
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Table 9.  
Non-Steroidal Anti-inflammatory Drugs 
NSAIDS                      Dosage              Interval               (Inpt) n       %       (Outpt) n         %             
             Ketorolac       15mg-30mg        Every 6 hours        75          100         24             100    
             Ibuprofen       400mg-800mg    Every 4-6 hours       0              0          0                  0 
             Naprosyn       500mg                Every 12 hours        0              0          0                  0 
Route                                    (Inpatient) n          %            Outpt)n       %______        ______  
             IV                                        67           93.1                        22            95.7 
             Oral                                      5             6.9                          1              4.3 
             No documented data          45                                          28               
Doses Administered         (Inpt)   n             %              (Outpt) n                  %_____________ 
             1                                21                  29.2                    11                    47.8  
             2                                31                  43.1                     6                     26.1 
             3                                16                  22.2                     4                     17.4 
             4                                 4                     5.5                     2                      8.7 
   No documented data           45                         __________28___               ____________  
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Table 10.  
Inpatient Adjuvants  
Adjuvants              Dosage          Interval                n    percentage      Indication    n       (%)__ 
       Benadryl      25mg-50mg       4-6 hours           45        59.2          Pruritus        44     57.9 
       Atarax          25mg                 4-6 hours            1          1.3           Pruritus         1       1.3 
       Zofran          4mg-8mg           4-6 hours           16        21.1          Nausea        16    21.1 
       Baclofen      10mg                  8 hours               2          2.6            Spasms        2      2.6 
       Lyrica           50mg-600mg     12 hours             4          5.3            Pain              4      5.1 
       Neurontin     100mg-900mg   8-12 hours          3          3.9            Pain              3      4.1 
      Ativan            0.25mg-1mg      6-12 hours          5          6.6             Anxiety        6     7.9 
No documented data                                               41                                               66   ____   
Route                                                    n                                          Percentage ___________ 
      IV                                                    19                                            24.7 
      Oral                                                 58                                           75.3 
      No documented data                      40                                                 _________________ 
Number of Doses Administered              n                                       Percentage__________ 
      1                                                           29                                            39.2 
      2                                                           21                                            28.2 
      3                                                            9                                             12.2 
      4                                                            7                                               9.5 
      5                                                            3                                               4.1 
      6                                                            4                                               5.4 
      7                                                            1                                               1.4 
     No documented doses                          43                                                   _____________  
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Table 11.  
Observation Adjuvants 
 
Adjuvants            Dosage              Interval                  n       (%)           Indication      n       (%)_  
      Benadryl      25mg-50mg        4-6 hours              17      60.7             Pruritus       17     60.7 
      Atarax          25mg                  4-6 hours               1        3.6              Pruritus         0          0 
      Zofran          4mg-8mg            4-6 hours               5      17.9             Nausea         5      17.9 
      Baclofen      10mg                   8 hours                  0          0              Spasms         0         0 
      Lyrica           50mg-600mg      12 hours                1        3.6             Pain              1       3.5 
      Neurontin     100mg-900mg     8-12 hours            1        3.6             Pain              1       3.5 
      Ativan           0.25mg-1mg        6-12 hours            3      10.6            Anxiety          4      14.4 
      No documented doses                                        23                                             23________                      
Route                                               n                                     Percentage _________________ 
      IV                                                8                                           28.6 
      Oral                                            20                                         71.4 
      No documented data                 23                                        _        ____________________ 
Number of Doses Administered              n                                        Percentage__________ 
      1                                                            10                                            35.7 
      2                                                            13                                            46.4 
      3                                                             3                                            10.7 
      4                                                             0                                                 0 
      5                                                             1                                              3.6 
      6                                                             0                                                0 
      7                                                             1                                              3.6 
      No documented doses                           43                                                  ______________  
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Exhibit A. Sickle Cell Infusion Order Set Sample 
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Exhibit B. SCD Order Entry Set Sample 
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Exhibit C. SCD Order Set Sample A 
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Exhibit D. SCD Order Set Sample B 
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Exhibit. E SCD Order Set Sample C 
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Exhibit F.  Clinical Dashboard Sample  
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Exhibit G. Clinical Dashboard Sample A 
 
 
 
 
122 
 
Exhibit H. Clinical Dashboard Sample B 
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